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Summary 
Vertebrates have developed an effective and protective, yet complex and dynamic immune system 
to defend themselves against the many threats from microorganisms. Although considerable 
advance in our understanding of B lymphocyte development have been made in recent years, still 
many questions are in debate and new questions have emerged. In this thesis some of the questions 
regarding the regulation of murine B cell development and function have been addressed.  
In the first part (chapter 3) it was investigated whether the quality of the pairing interaction 
between the µH chain and the surrogate light (SL) chain of a given pre-B cell receptor may 
determine the size of the clonal expansion at the large pre-B II cell stage in the bone marrow (BM). 
VHDHJH-rearrangements derived from pre-B cells having proliferated to different extent in vitro in 
the absence of any added cytokines were isolated and analysed for their sequences and pairing 
capacities. It could be shown that the capacity of µH-SLC pairings can be measured not only as an 
all-or-nothing event, but at least also semi-quantitatively. To this end, the present study shows a 
tendency of a better pairing capacity for VHDHJH-rearrangements derived from cells, which have 
undergone more cell divisions.  
In the second part (chapter 4) the effect of TSLP in lymphocyte development was investigated. It 
could be shown that increased TSLP availability through transgene expression fully restored 
lymphopoiesis in IL-7 deficient mice. It rescued B-cell development, increased the thymic 
cellularity, and rescued the thymic architecture in IL-7-/- mice. Adult wt bone marrow cells 
differentiated normally into B and T lineages and restored peripheral compartments when 
adoptively transferred into lethally irradiated IL-7-/- TSLP Tg recipients. Moreover, it could be 
shown that B cells generated in IL-7-/- TSLP Tg mice originated from adult precursors as these B 
cells contained N nucleotide additions in their IgH junctions. 
In the third part (chapter 5) the expression of BAFF-R on murine BM B cells was investigated with 
the use of novel monoclonal anti-mBAFF-R antibodies. We found that expression of BAFF-R is 
first detectable by flow cytometry (FACS) on a fraction of CD19+ CD93+ IgM+ CD23- BM B cells. 
This BAFF-R+ BM B cell population showed higher levels of surface IgM expression and 
decreased recombination-activating gene 2 (RAG-2) transcripts than BAFF-R- immature B cells. 
When cultured in vitro, BAFF-R+ immature B cells did not undergo further B cell receptor 
rearrangement, while BAFF-R- immature B cells did. However, when cultured in the presence of 
an anti-kappa light chain antibody, BAFF-R+ immature B cells could be induced to undergo 
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receptor editing and this correlated with the upregulation of RAG-2 and the downregulation of both 
surface IgM and BAFF-R expression. Addition of BAFF did not inhibit this induced receptor 
editing. We concluded, that expression of BAFF-R can be used as a marker to identify immature B 
cells, which under normal conditions no longer undergo BCR editing, but can still be induced to do 
so by BCR engagement. 
In the fourth part (chapter 6) a putative new B cell population was phenotypically and functionally 
characterized. These cells, in this study termed ‘newB’ cells, were defined by the expression of 
CD19+ CD93- CD21-/lo CD23-/lo CD5-. They are small in size, comparable to follicular B (FOB) 
cells, and represent 2% of CD93-, mature B cells in spleens of wild-type C57BL/6 mice. In 
addition, newB cells were detected in lymph nodes. However, the analysis of surface markers 
suggests that newB cells have a less mature phenotype. In addition, they showed a high turn-over 
in vivo as compared to other mature B cell populations, but lower as for transitional B cells. In 
functional assays newB cells showed only a limited response to LPS, α-IgM and α-CD40 as 
compared to FOB and marginal zone B (MZB) cells. The findings of the analysis of λ1 light chain 
sequences demonstrated that newB cells are not subjected to somatic hypermutations and hence, 
most probably, do not belong to germinal center B cells and B cell memory. The collected data so 
far supports the idea that newB cells could represent an additional intermediate cell population in 
the transition of immature to mature B cells. However, this is in conflict with the detection of these 
cells in lymph nodes. Alternatively, newB cells could represent cells, which for as yet, unknown 
reasons get selected out from the pool of mature, reactive B cells later, because they do not fulfill 
criteria to remain and therefore are rendered anergic and regain a more immature phenotype. 
In the last part (chapter 7) the differential response of splenic mature B cells to the mitogen 
lipopolysaccharide (LPS) was investigated. It was known that frequencies of LPS-reactive B cells 
in C57BL/6 mice is higher than in BALB/c mice. In this study, it could be shown that actually the 
FOB cells of C57BL/6 respond stronger to LPS in vitro than FOB cells of the BALB/c strain. In 
this study, MZB cells of both mouse strains showed a stronger response to LPS than the FOB cells. 
However, in contrast to the observation in FOB cells, MZB cells of both tested strains responded 
equally strong. A genetic approach did not lead to the identification of a responsible locus for the 
observed differential response in FOB cells, but indicated that most probably multiple genes 
control the response in a differential fashion in FOB cells in the tested mouse strains. Furthermore, 
the results suggest that the stronger response of FOB cells from C57BL/6 mice either involves 
components within the MyD88-dependent pathway or components, which can modulate the 
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MyD88-dependent signaling pathway. In addition and in contrast to another study, we could show 
that the observed differential response is not determined by the MHC class II haplotype in these 
strains. 
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1 GENERAL INTRODUCTION 
During evolution organisms have always been in competition with other organisms. Numerous 
mechanisms have evolved to attack and to defend against various other competitors. Thus, highly 
developed vertebrates are constantly exposed to potentially pathogenic threats from 
microorganisms, like bacteria, viruses, fungi and nematodes. Vertebrates have developed an 
immune system, an effective and protective, yet complex and dynamic system to defend 
themselves against these threats from microorganisms. This potent system can be separated into 
two interacting branches. The innate immune system is more unspecific, relying on barriers 
involving anatomic, physiologic, endocytic and inflammatory mechanisms against a wide variety 
of pathogenic threats. The other is the adaptive immune system, which consists of B and T cells. 
Each of these lymphocytes carries unique cell surface receptors, which distinguishes self from 
nonself structures (called antigens) and which will therefore bind to invading pathogens or 
molecules produced by them. Following binding, B and T cells of the adaptive immune system 
respond by proliferation and differentiation into effector cells as well as memory cells with 
increased lifespan. Because of the large diversity of their antigen specific receptors, B cells and T 
cells can respond to virtually any kind of foreign antigen. 
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1.1 B lymphocytes 
B cells recognize antigens via their B cell receptor (BCR). After interacting with antigen they can 
differentiate into plasma B cells, which then secrete the soluble form of the B cell receptor as an 
antibody. These secreted immunoglobulin (Ig) molecules can bind to free antigen and thereby 
mediating the clearance of the antigen from the organisms. Ig molecules binding to antigens on 
surfaces of invaders can activate the complement system resulting in the formation of pore forming 
complexes at the surface of these invaders, which results in their destruction by lysis. Ig molecules 
may also bind with their Fc moieties to Fc receptors on cells of the innate immune system, namely 
monocytes, macrophages, granulocytes, mast cells and natural killer cells. Thereby, the high 
diversity of the Ig molecules mediates more specificity to, for example, NK cells of the innate 
immune system in the antibody dependent cellular cytotoxicity (ADCC) reaction. The diversity and 
specificity are properties of the adaptive immune system and are generated during the development 
of B and T cells. 
1.2 The B cell receptor (BCR) 
1.2.1 Organization of the B cell receptor complex and its genomic locus 
The basic structure of a B cell receptor and its secreted form, termed antibody, consists of two 
identical heavy and two identical light chains. Each of the two light chains are covalently linked by 
a disulfide bond to one heavy chain, which in turn are also covalently linked by a variable number 
of disulfide bonds, depending on the isotype of the heavy chain. Heavy and light chains contain 
several protein domains. Each of the domains has a characteristic tertiary structure called the 
immunoglobulin fold. The immunoglobulin fold consists of two β-pleated sheets folded into a 
globular domain, therefore the resulting molecules are so-called immunoglobulins (Igs). The 
amino-terminal region (110 aa), called variable (V) region, in each heavy- and light chain contains 
the antigen-binding site and varies greatly among antibodies of different specificities. The 
variability in the V regions is not uniformly distributed, but is concentrated into three hypervariable 
regions, comprising loops of the β-pleated sheets. These regions are called complementarity-
determining regions (CDRs) and form most of the antigen-binding site. The remainder of each 
heavy chain contains three or four constant domains (CH1-3(4)), while the remainder of each light 
chain consists of only one constant domain (CL). 
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Immunoglobulins are expressed in two forms: membrane-bound as a B cell receptor (BCR) on 
resting B cells and secreted as an antibody from plasma cells. This variation depends on alternative 
splicing of the primary mRNA including the trans-membrane region encoding exon or a nucleotide 
sequence coding for the hydrophilic tail of the secreted form (1, 2). For successful surface 
deposition of the BCR, the molecule has to associate with the heterodimeric membrane protein Ig-
α/Ig-β (encoded by the mb-1/B29 genes) (3). 
A complete heavy chain is encoded by a variable region gene segment (VH), a diversity gene 
segment (DH), a joining gene segment (JH) and the constant gene segments (CH1-3(4)), the last 
expressing the constant region while the others form the variable region. In contrast to the heavy 
chain variable region, the light chain variable region (VL) is encoded only by a variable and a 
joining gene segment (4). Each gene segment is a member of a cluster of gene segments located in 
three different genomic loci. 
 
Figure 1. Schematic representation of mouse Ig genomic loci. 
Genomic organization Ig of heavy and light chain loci containing variable (V), diversity (D), joining (J) and 
constant region (C) gene elements; pseudogenes (Ψ).  
In mice, the Ig heavy (IgH) chain locus is found on chromosome 12. The locus spans over 2.4 Mb 
and contains the clusters coding for 170 variable (V1-170) in 15 VH families, 13 diversity (D1-12), 4 
joining (J1-4) and 8 constant (Cµ, δ, γ3, γ1, γ2b, γ2a, ε, α) gene segments (4, 5). Based on the 
coding sequence homology, VH gene segments in mice are grouped into 15 families. Family 
members can be clustered but some members from various families are interspersed (6-11). 
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The κ light chain locus is located on chromosome 6 containing 140 (of which 96 are functional) 
Vκ genes (12), 5 (4 functional) Jκ genes and 1 Cκ gene segment. The λ light chain locus, located on 
chromosome 16, consists of only 3 Vλ, 3 Jλ and 3 Cλ gene segments. 
Both, the heavy- and the light-chain loci include also pseudogene segments. It could be shown for 
the V regions of the heavy-chain locus that these pseudogenes are not evenly distributed over the 
locus but rather form clusters (13) (Figure 1). 
1.2.2 V(D)J recombination process 
The diversity of antigen receptors on B cells is generated by a somatic gene rearrangement process, 
where single variable (V), in the case of the heavy chain also diversity (D) and joining (J) gene 
segments are recombined. This mechanism is referred to as V(D)J recombination (4). Developing 
B lymphocytes rearrange their V, (D) and J gene segments in an orderly and stepwise fashion. 
Thus, the H chain locus is always rearranged before the L chain locus. In case of the heavy chain 
gene rearrangement, a D element is first rearranged to a J gene segment, followed by a subsequent 
V to DJ rearrangement (4, 14). In the light chain gene rearrangement V and J gene elements are 
directly joined to form the complete V segment.  The order of the V(D)J recombination process is 
determined by the temporal accessibility of the different loci to the recombination machinery by 
mechanisms including subnuclear relocation, chromatin remodeling, DNA methylation, histon 
acetylation and germline transcription (15-20). 
The recombination machinery recognizes DNA sequences called recombination signal sequences 
(RSS), adjacent to each V(D)J gene segment. Each RSS consists of a conserved palindromic 
heptamer and an AT-rich nonamer sequence separated by either a 12- or a 23-base pair spacer. 
Recombination occurs only between two segments flanked by RSS with different spacer length: the 
so-called 12/23bp spacer rule (21). The recombinase is made up of a complex consisting of 
recombinase activating gene-1 (RAG-1) and RAG-2, which, in conjunction with the non-specific 
DNA-bending proteins, High mobility group protein 1 and 2 (HMG-1 and HMG-2), recognize the 
RSS, where a site-specific DNA cleavage is catalyzed (22, 23). The RAG proteins introduce a 
double-strand DNA break precisely between the V, D or J coding sequences and the RSS. Initially 
RAG introduces a single strand nick. The released 3’-OH group of the coding gene segment attacks 
via transesterification the phosphodiester bond on the opposite DNA strand leading to blunt signal 
ends and hairpins at the coding ends (23). General DNA repair factors of the nonhomologous end 
joining (NHEJ) DNA repair pathway are then recruited to perform processing and ligation of the 
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DNA ends (24-26). Prior to joining the coding ends, the hairpins must be opened. The opening of 
the hairpins frequently occurs off-center, leading to palindromic single-stranded tails. 3’ overhangs 
have to be trimmed before ligation, unless both coding ends have complementary overhangs. 5’ 
overhangs can be filled in, giving rise to short palindromic (P nucleotide) insertions (27). During 
the rearrangement of the heavy-chain gene segments occasionally up to 15 nontemplated 
nucleotides (N nucleotides) are added to the coding ends by the terminal deoxynucleotidyl 
transferase (TdT). 
Combinatorial recombination of V, D and J gene segments, junctional diversification due to 
imprecise processing of the coding ends and N-nucleotide additions, as well as combinatorial 
heavy-light chain pairing can produce a giant repertoire (>108) of possible antigen receptors. 
1.3 B cell development 
In the mouse, B cells develop from pluripotent hematopoietic stem cells in the liver during mid-to-
late fetal development and in the bone marrow after birth (28). The differentiation of precursor 
cells along the developmental pathway from the B lineage-committed progenitor to the mature 
antigen-sensitive BCR-expressing B cell is characterized by changes in the expression pattern of 
molecular markers. Along this pathway different checkpoints guarantee that competent B cells 
develop. This includes elimination or silencing (anergy) of cells with a non-functional BCR or 
cells, which bear a potentially harmful receptor recognizing autoantigenes. 
1.3.1 B cell development in the bone marrow 
Hematopoetic stem cells are pluripotent and can develop into cells of the lymphoid, myeloid or 
megakaryocyte-platelet or erythrocyte pathways. 
A common lymphoid progenitor (CLP) subset, which has lost the myeloid potential, has been 
characterized by lack of the lineage markers CD45R/B220, CD11b/Mac-1 and GR, but expression 
of CD117 (c-kit) and the IL-7R α-chain (29, 30). 
This model is now being questioned and current findings (31) support the model (32) that 
development proceeds rather through separate B and T cell progenitors retaining myeloid 
differentiation potential than through the postulated CLP, which has lost the myeloid potential. 
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The different stages of B cell development have been characterized by their marker expression and 
rearrangement status at the IgH and IgL loci. Different nomenclatures for the different stages of B 
cell development have emerged from various research groups (33-35). In this thesis the 
nomenclature from Rolink and Melchers will be used (Figure 2). 
 
 
Figure 2. Schematic representation of B cell development in the bone marrow. 
B cell development in mice after birth starts from hematopoietic precursors in the BM. The different stages 
of development have been characterized by their marker expression and rearrangement status at the IgH and 
IgL loci. Nomenclature used is according to Rolink and Melchers ((35)). 
The earliest B cell progenitor, the pre/pro-B cell, is phenotypically defined by the pan B cell 
marker B220 (CD45R), IL-7Rα (CD127) chain and c-kit (CD117) (36-38). At the pro-B cell stage, 
cells start to express the BCR complex component CD19, which is then expressed on all later B 
cell stages, except the plasma cells. The CD19 gene is a direct target for the Pax-5 (BSAP) 
transcription factor. Pax-5 is crucial for maintaining B cell lineage commitment (see later) (39, 40). 
Pro-B cells start to rearrange their DH and JH gene elements in their IgH loci and develop into preB-
I cells, which have DJH rearrangements, often on both IgH alleles. Furthermore, the pre-B cell 
receptor (pre-BCR) components VpreB and λ5 are expressed. Pre-B I cells are similar to pro-B 
cells with respect to intracellular and surface marker expression and cell cycle status. They 
maintain the capacity to proliferate on stem cell factor expressing stromal cells in the presence of 
the cytokines IL-3 or IL-7. 
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Pre-B I cells start to rearrange a VH chain gene element to the DJH segments, thus finalizing the 
rearrangement of a µH chain. Initially only one allele is rearranged. If the rearrangement is 
successful, i.e. in-frame, RAG-1/2 and TdT expression are downregulated (41) and the cells start to 
express the µH chain protein, a hallmark of pre-B II cells. At this stage pre-B II cells gain IL-2R α 
chain (CD25) expression (35) but have lost c-kit expression and are therefore not expandable any 
longer in stromal cell cultures. Pre-B II cells can be further subdivided into cycling large pre-B II 
and resting small pre-B II cells (35). In approx. 25% of large pre-B II cells the µH chain is 
expressed together with the surrogate light chain (SL chain) at the cell surface as a pre-BCR. This 
surface expression is dependent on a successful pairing interaction with the VpreB and λ5 
components of the SL chain, components of the pre-BCR, which together resemble the λ light 
chain, and mounts an important checkpoint in pre-B cell development. Successful pairing leads to 
the clonal expansion of the large pre-B II cells through 2-5 rounds of division and the cells then 
become resting small pre B II cells, which have lost pre-BCR expression (42). Mutations affecting 
the rearrangement, the µH chain expression or the SL chain expression (35, 43-49), all lead to a 
severe reduction in pre-B II cells, and none of them are cycling, stressing the importance of pre-
BCR expression in driving the clonal expansion. 
If rearrangement at the first allele did not succeed in producing a functional pre-BCR, the cell may 
retry a VH to DJH rearrangement at the other allele, or else go into apoptosis. It is estimated, that, at 
least, 40% of emerging pre-B cells die during this process. 
Upon re-expression of the recombination machinery, small pre-B II cells start to rearrange their IgL 
chain gene loci. In mice, the majority of rearrangements are found in the κL chain loci, resulting in 
a 10:1 κL versus λL chain ratio among BCRs. This ratio remains stable also in the peripheral B cell 
pool (50) and among serum immunoglobulins. 
Cells with a successful light chain rearrangement become surface IgM (sIgM) positive immature B 
cells expressing CD19, intermediate levels of B220 and low to high levels of sIgM.  
Some of the immature B cells expressing a BCR with affinity for autoantigens may become 
negatively selected and die in the bone marrow. The interaction with antigen results in down-
regulation of sIgM and B220 (51). As apoptosis is not a sudden death event and since these cells 
still express and may even up-regulate the RAG-1/2 enzymes (52) they have been reported to 
undergo receptor editing through a secondary light chain gene rearrangement, trying to escape the 
negative selection (53, 54). 
In adult mice (6-8 weeks) 2x107 of these immature cells are produced daily (55, 56), and 10-20% 
of them (57) will enter the spleen but only 5-10% will enter the pool of long-lived mature B cells 
(58) after final maturation in the spleen. 
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1.3.2 The pre-B cell receptor complex 
The pre-B cell receptor complex (pre-BCR) at the B cell surface comprises the µH chain, the 
surrogate light chain with its components VpreB and λ5, and the transmembrane heterodimer Ig-
α/Ig-β (Figure 3). 
The genes coding for two functional VpreB proteins (VpreB1 and VpreB2) and λ5 are located on 
chromosome 16 in mice (59, 60). The VpreB proteins are highly homologous and seem to form a 
variable region-like structure (61, 62). The constant region-like λ5 protein has a C-terminal Ig 
domain, followed by the seventh β-strand of a V domain encoded by a J-like region of the gene and 
an N-terminal non-immunoglobulin domain. Only when λ5 is non-covalently associated with 
VpreB will the λ5 protein form a disulphide bond with the first constant region (CH1) of a µH chain 
capable of pairing. The Ig domains of λ5 and VpreB are responsible for their non-covalent 
association (63, 64). The genes encoding Ig-α and Ig-β glycoproteins proteins, mb-1 and B29, are 
located on chromosome 7 and 11, respectively. The disulfide-linked transmembrane heterodimer 
Ig-α/Ig-β associates with the µH chain of the membrane-bound pre-BCR. The cytoplasmic tails of 
both Ig-α and Ig-β proteins contain tyrosine-based activation motifs (ITAM), which couple the pre-
BCR complex to intracellular signal transducers (3, 65, 66). 
Figure 3. Pre-B cell receptor complex. 
Pre-BCR complex comprises the µ heavy chain 
(µH), surrogate light chain (SLC) components 
λ5 and VpreB and heterodimeric Ig-α/Ig-β. 
CHAPTER 1  GENERAL INTRODUCTION 
   
 
 9 
1.3.3 Pre-B cell receptor signaling 
After an in-frame VHDHJH rearrangement, a µH chain protein is produced. Initially the translated 
µH chain is associated with the endoplasmatic reticulum-resident chaperon protein BiP (67, 68). 
Later, the BiP can be replaced by a successful pairing of the µH chain with the surrogate light 
chain (SL chain) (62), which leads to the translocation of the pre-BCR to the cell membrane where 
it forms the pre-BCR complex together with the transmembrane heterodimer Ig-α/Ig-β. As the pre-
BCR itself lacks an intrinsic signaling capacity, the non-covalent pairing with the signaling 
molecule Ig-α/Ig-β to form the pre-BCR complex is required. Indeed, the expression of Ig-α/Ig-β 
in the absence of a µH-chain is sufficient to deliver a ligand-independent tonic signal in pre-B cells 
that can trigger early bone marrow and limited peripheral B cell maturation (69). 
1.3.4 Allelic exclusion and pre-BCR signaling 
Recombination of V, (D) and J gene segments occurs in a lineage- and stage specific manner. 
At the pre-BCR stage, developing B cells are monitored for the production of a heavy-chain which 
is competent to pair with a light-chain giving rise to a single specific antigen receptor. The stepwise 
process of first rearrangement on only one IgH locus together with functional testing for pairing 
with the SL chain, as the pre-BCR ensures that a given B cell will finally express only one 
functional antigenic receptor, thus avoiding cells with multiple specificities, which, in theory, could 
result in more than 25 different specificities expressed on a single B cell. This mechanism has been 
termed allelic exclusion (70, 71). In 2-4% of all B cells, the cell contains two productively VHDHJH-
rearranged H chain alleles. However, only one of the µH chains is capable of pairing with the SL 
chain (72). The mechanism of allelic exclusion is as yet not fully understood. It was suggested that 
the SL chain is involved and therefore that a defective SL chain might prevent allelic exclusion. 
However, the absence of the λ5 component does not abolish allelic exclusion, but rather prevents 
the proliferative expansion at the large pre-B II stage (42, 72). A similar phenotype has been 
described for the double-deficient VpreB1-/-VpreB2-/- mice (46). In contrast, the absence of the 
transmembrane region of the µ H chain in µMT mice results in a loss of allelic exclusion. 
Furthermore, in transgenic mice, the membrane form, but not the secreted, of a µH chain leads to 
allelic exclusion of the endogenous IgH chain loci indicating that the transmembrane form is 
necessary to maintain allelic exclusion (44, 70, 73). 
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It has been shown that pre-BCR signaling leads to a rapid loss of RAG protein expression and 
therefore the inactivation of the recombination machinery, which results in the inhibition of further 
V(D)J recombination and, therefore, establishes the basis for allelic exclusion (41). In addition, 
pre-BCR signaling in large pre-B cells induces rapid decontraction of the genome and recruitment 
to repressive centromeric domains of the Ig heavy-chain locus, which aids in the prevention of 
further VH-DJH rearrangement at the second allele during the course of Ig light-chain 
rearrangements later in small pre-B cells. However, the four most proximal VH genes can escape 
allelic exclusion as has been shown in µ-transgenic B cells, since the rearrangements of these genes 
do not depend on locus contraction (74). This is in accordance with data, which showed that the 
rare allelically included B cells, which express two different µH proteins, have a disproportionately 
high frequency of proximal VHQ52-DHJH and VH7183-DHJH rearrangements (75). 
1.3.5 B cell maturation in the spleen 
IgMhi immature B cells transit from bone marrow via blood into the spleen through the terminal 
branches of central arterioles and marginal sinuses into the outer zone of the periarteriolar 
lymphoid sheath (PALS) (76, 77). In the spleen the immature B-cell compartment can be further 
subdivided into three sequential, transitional B cell stages, of short-lived  (t1/2 = 2-4 days) 
transitional 1 (T1), T2 and T3 cells (57, 78, 79). The transitional compartment is characterized by 
the expression of the complement component C1q-like receptor C1qRp (CD93) recognized by the 
493 (57) or the AA4.1 antibody (78). T1 cells are CD19+ CD93+ CD21-/lo CD23- IgMhi IgDlo and 
appear to be localized at the outer limits of the PALS. T2 cells become CD21+ CD23+ IgDhi and 
migrate to the B cell follicles (76, 79). In T3 cells, IgM expression is lower as in cells of the T2 
stage (IgMint). Functional analysis showed that BCR crosslinking induced apoptosis in T1 and T2 
cells whereas T3 cells responded with proliferation (78, 80). Nevertheless, there is a disagreement 
in the literature, whether the change in responsiveness takes place or not already at the T2 stage 
(81). In normal mice the ratio of the different transitional cell subcompartments (1:1:1) remains 
stable with age while the relative size of the immature compartment decreases with respect to all B 
cells in the spleen (80) (Figure 4). 
Mature B cells can be discriminated from all the different immature B cell populations by their 
CD93 negative phenotype (Figure 4). The largest population (~90%) of mature B cells in the 
spleen comprises the relatively long-lived (t1/2 approx. 4.5 months) follicular B cells (FOB) (82). 
As their name implies, they are located inside follicles and are mainly involved in T cell dependent 
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(TD) immune responses. FOB cells are characterized by the CD19+ CD93- CD21+ CD23+ IgM+ 
IgDhi set of surface markers. Normally resting, upon activation they enter germinal centers, where, 
with the support of T cells, their antigen receptor genes undergo somatic hypermutations, which 
eventually leads to cells bearing receptor molecules with a higher affinity for antigen and the 
production of highly specific antibodies. FOB cells can recirculate to other lymphoid tissues 
including lymph nodes and the bone marrow. 
Another type of mature B cells in the spleen, although less abundant (~5%) than the FOB cell 
population, are the marginal zone B (MZB) cells (Figure 4). They are located in the marginal zone, 
which is in close proximity to the marginal sinus, making them particularly well positioned to 
respond rapidly to blood-borne antigens. In contrast to the recirculating FOB cells, MZB cells are 
relative sessile and not part of the recirculating pool of lymphocytes (83). MZB cells have a CD19+ 
CD93- CD21hi CD23-/lo IgMhi IgDlo phenotype. It has been suggested that MZB cells are mainly 
involved in T cell independent type 2 (TI-2) responses against multivalent antigens (84-90), since 
splenectomy as well as mutations in certain signaling pathways resulting in the absence of MZB 
cells correlated with an increased susceptibility to encapsulated bacteria. MZB may mature rapidly 
into plasmablasts. Thus, within the first three days following exposure to blood-borne pathogens, 
antigen-specific MZB cells proliferate concomitantly with their differentiation into IgM-secreting 
plasmablasts (91, 92). In in vitro stimulation assays, MZB cells proliferated stronger than follicular 
B cells when stimulated with lipopolysaccharide (LPS), CD38 cross-linking or CD40 ligation and 
secreted more IgM and IgG3 molecules (93). 
There is growing evidence that MZB cells are also involved in T-dependent immune responses. 
MZB may also become potent antigen presenting cells (APCs) since they express higher levels of 
MHC class II and CD80/86 molecules than FOB cells and are thus, potent activators of naïve CD4+ 
T cells (92, 94). 
Both, FOB and MZB cells belong to the B-2 subset of mature B cells. 
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Figure 4. Schematic representation of B cell development in the spleen. 
BM: bone marrow, T: transitional type B cells, FOB: follicular B cell, MZB: marginal B cell, B1-a/b: type 1 
B cells. Immature stages (green), mature stages (blue) defined by CD93 expression. 
The B-1 B cells, which represent only a minor fraction of B cells in the spleen, but represent the 
major B cell population in the peritoneal and pleural cavities were originally characterized by their 
B220lo IgMhi CD23- CD43+ IgDlo phenotype. They also have a larger size and exhibit more side 
scatter than do B-2 B cells. Furthermore, they can be subdivided into CD5+ B-1a and CD5- B-1b 
subpopulations. In addition, B-1 cells in the peritoneal and pleural cavities are Mac-I+ (CD11b), 
while they are Mac-I- in the spleen (Figure 4). In contrast to the FOB cells, B-1 B cells are rarely 
found in lymph nodes. Furthermore, for B-1a B cells it has been shown that they require the spleen 
for their generation and maintenance (95). 
These cells mainly participate in responses to T-independent type 2 (TI-2) antigens. They are also 
the major producers of polyreactive, weakly autoreactive, naturally occurring serum IgM 
antibodies. Such antibodies seem to be produced in the apparent absence of exogenous antigenic 
stimulation (91, 96-98). B-1 B cells activated in the peritoneal and pleural cavities rapidly migrate 
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into the spleen and gut lymphoid tissues, where they lose CD5 expression and differentiate into 
antibody-secreting plasma cells (99, 100). 
Compared to B-2 B cells, the B-1 cell compartment contains a high frequency of cells with 
specificities towards self-antigens, like phosphatidyl choline (PtC) and both single and double 
stranded DNA, as well as common bacterial carbohydrate antigens such as phosphorylcholine (PC) 
(97, 98). It has been suggested that the development of B-1 B cells reflects differences in fetal and 
adult B cell development due to the fetal origin of the majority of CD5+ B cells (101) and that BCR 
specificity plays an important role (102, 103). Originally, it was proposed that B-1 B cells are 
derived from different, committed, precursors than the B-2 B cells. This was based on transfer 
studies where fetal liver reconstituted the B-1 and B-2 compartments in irradiated recipient mice, 
while adult bone marrow was limited to the generation of B-2 B cells (104, 105). Other 
experiments suggest an “induced-differentiation” model where encounters with naturally occurring 
TI2 antigens account for the appearance of B-1 B cells in vivo (106, 107). The fetal and neonatal 
repertoire is skewed towards the expression of immunoglobulins that frequently bind encountered 
TI-2 antigens while the adult repertoire generates less of these specificities and therefore generates 
fewer B-1 B cells (108, 109). Further support for the “induced-differentiation” model comes from 
studies showing that the quality of B cell receptor signaling is essential for B-1 B cell development. 
Mutations that disrupt BCR signaling result in a strong reduction of the B-1 B cell compartment, 
while enhancing BCR signaling results in an expanded B-1 compartment (110, 111). Studies with 
mice transgenic for a single Ig molecule with B-1 specificity, showed a reduction of the B cell 
receptor surface density by a factor of only two, but significantly reduced the number of transgene 
expressing B-1 B cells. (112, 113). 
Nevertheless, recently a B-1 B cell-restricted progenitor has been described, which numbers are 
highest in fetal bone marrow, but were lower in adult bone marrow and supports the model that B-1 
cells develop from unique progenitors (114). 
1.3.6 Factors regulating B cell maturation and lineage commitment 
Many factors influencing B cell maturation and lineage commitment are known but the exact 
mechanism of action remains to be elucidated. Naturally occurring and genetically engineered 
mutations are valuable tools helping to shed light on the factors and mechanisms involved in 
lineage commitment. 
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1.3.6.1 Transcription factors 
Differentiation of the common lymphoid precursor (CLP) to committed pro-B cells depends on the 
transcription factors E2A, EBF, and Pax5 (115). 
1.3.6.1.1 E2A and EBF (Early B cell Factor) 
E2A, a basic helix-loop-helix (bHLH) protein with two splice forms E12 and E47 (116), is widely 
expressed in tissue as a heterodimer with tissue-restricted other bHLH proteins, but specifically 
functions as a homodimer in the B cell lineage (117). Together with EBF, which also is expressed 
as a homodimer and recognizes DNA via the N-terminal domain containing a zinc finger motif 
(118, 119). E2A controls the earliest phases of B cell development. Studies with E2A or EBF 
mutant mice showed a similar arrest of early B cell development in both mice with the Ig heavy-
chain locus remaining in germline configuration (120). This suggests that the two factors act in 
concert to regulate the expression of multiple B-lymphoid genes including the RAG1 and RAG2 
genes (121). Moreover, it could be shown that the E2A and EBF proteins bind to and cooperatively 
activate the promoters of the SL chain-components λ5, VpreB, and the pre-BCR complex 
component Ig-α (122-125). EBF was in addition shown to control the Ig-β promoter (126).  
1.3.6.1.2 Pax-5 (BSAP; B-cell-specific activator protein) 
The Pax5 gene is located at chromosome 4 and encodes a member of the paired box (PAX) family 
of transcription factors. It contains a highly conserved DNA-binding domain, known as the paired 
box, a repression, and a transactivation domain. The paired domain is composed of two 
subdomains that bind to the two half-sites in adjacent major grooves at the same side of the DNA 
helix (127-129). 
Pax5 is crucial for maintaining the B cell lineage commitment (39) since Pax5-deficiency blocks 
the B lymphopoiesis at the pre-B I cell stage (130, 131). In addition, in mice where the Pax5 gene 
can be conditionally removed, the inactivation of Pax5 leads to the loss of phenotypes and 
functions of mature B cells (132). However, transferring cultured Pax5-deficient pre-B cells into 
irradiated recipients gives rise to long-term in vivo reconstitution of T cells (40). The Pax5 protein 
supports the B-cell commitment by activating lineage-specific genes, i.e. CD19, and repressing 
lineage inappropriate genes, such as M-CSR, Notch1, Flt3 (133-135). Furthermore, Pax-5 has an 
important role in regulating the contraction of the Ig heavy-chain locus (136). Thus, Pax-5-/- pro-B 
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cells fail to rearrange the central and distal VH gene elements in an otherwise fully accessible and 
active chromatin (137). 
1.3.6.2 Role of the BCR and BCR signaling 
Expression of the BCR is required for the survival of all B cells. In mice where the BCR can be 
conditionally removed from B cells, such modified cells rapidly disappear from the circulation and 
from lymphoid organs (138). Both the affinity of a given BCR to its antigen and the surface density 
of BCR may also determine the lineage-fate of B cells (112, 113, 139). Furthermore, the specificity 
of the expressed BCR may influence the lineage decision. In contrast to FOB cells, the 
differentiation into MZB and B-1 cells is dependent on self or environmental antigens, such as 
phosphorylcholine and phosphatidylcholine, suggesting that these compartments require a positive 
selection mediated by interactions between BCR and antigen (140-143). However, in a recent 
study, it could be shown that a ligand-independent tonic signal may be sufficient to form FOB cells 
but not MZB or B-1 cells (69). 
There is ongoing discussion whether weak signals drive cells in the direction of FOB 
differentiation while strong signals preferentially result in the formation of MZB cells or that MZB 
cell development is driven by weaker BCR signals than those leading to FOB cell development. 
Deletion of the CD19 BCR complex component, a positive regulator of BCR signaling, leads to 
absence of MZB development and a reduction of the development of B-1 cells (110, 144), while 
over-expression of this complex results in an increase in the number of B-1b B cells as well as the 
breakdown of peripheral tolerance (145). Mice lacking the negative regulator CD22 are deficient in 
MZB cells (146) and also show an increased number of B-1b cells together with increased serum 
titers of autoantibody (147). In comparison, mice lacking the CD21 BCR complex component, 
show an enlarged MZB cell compartment and a decreased number of FOB cells. 
Conversely, the absence of the Aiolos transcription factor enhances the signal delivered by the 
BCR resulting in an increased FOB compartment and absence of MZB cells (148).  
And furthermore, CD5 expression in B-1a cells seems to be implicated in the negative regulation of 
B1 cells (100, 149). 
However, overall, the literature suggests that the lineage decision is driven primarily by differences 
in BCR signal strength. 
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1.3.6.3 Chemokines affecting the rate of B cell generation and survival may also 
affect lineage decision 
1.3.6.3.1 Interleukin-7 (IL-7) 
Interleukin-7 (IL-7) is produced by stromal cells in lymphoid tissues such as the bone marrow and 
is required for the normal development of lymphocytes. 
Early stages of B-cell development in adult mice depend upon IL-7 for growth, survival, and 
maturation. In the absence of interleukin 7 (IL-7), B lymphocytes are generated exclusively during 
fetal and perinatal life, but persist throughout adult life and consist only of cells that belong to the 
B1 and MZB compartments (150, 151). In contrast, mice overexpressing IL-7 as a transgene have 
an increased B cell generation in the bone marrow with a massive influx into the spleen, also of 
early B cell precursors, leading to splenomegaly. Analysis of mature B cells in the spleen of these 
IL-7Tg animals show a massive expansion of the FOB cell compartment without altering the MZB 
cell compartment. In mixed radiation bone marrow chimeras MZB cells developed to the same 
extent from wt and IL-7Tg adult bone marrow showing that IL-7 does not directly influence the 
lineage decision. The authors conclude that the number of cells in the FOB and MZB cell 
compartments may be independently regulated (152). These data support the model that the influx 
from the bone marrow to the spleen influences the lineage decision. While in a lymphopenic 
situation, the system preferentially propagates and maintains the B-1 and MZB compartments, an 
increased influx of progenitors from the bone marrow favors the FOB lineage decision. 
1.3.6.3.2 Interleukin-7 receptor (IL-7R) 
The interleukin-7 receptor (IL-7R) is expressed throughout B-cell development from the IL-7-
indepent CLP stage to the early surface IgM+ stage, but is not expressed in mature B cells. As for 
IL-7, an IL-7R-deficiency in adult mice blocks early B cell development already at the transition 
from CLP to pro-B cells (153-156).  
1.3.6.3.3 Thymic stromal lymphopoietin (TSLP) and its receptor (TSLP-R) 
The hemopoietic cytokine thymic stromal lymphopoietin (TSLP) signals through a heterodimeric 
receptor composed of the IL-7Rα and the thymic stromal lymphopoetin receptor (TSLPR) chain 
leading to the translocation of functional STAT5 to the nucleus. TSLP was originally cloned from a 
murine thymic stromal cell line. It promotes the homeostatic expansion of CD4+ T cells, enhances 
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dendritic cell maturation and triggers inflammatory allergic responses. The role in B cell 
development is less clear. TSLP was shown to support B-cell development in vitro (157), however, 
its role in B-cell development in vivo is controversial and some studies have suggested that TSLP 
might be limited to fetal rather than adult B-cell development (158-160). It is unknown whether 
these differences reflect distinctive TSLP responsiveness or availability of the cytokine in fetal 
versus adult hematopoiesis. 
1.3.6.3.4 Components of the Notch signaling pathway 
Notch signaling affects lineage decisions through the activation of a number of genes involved in 
the regulation of cell differentiation. 
The Notch family comprises four highly conserved transmembrane receptors that regulate 
differentiation in various tissues. Upon ligand binding, the intracellular domain is released through 
a proteolytic cleavage within the transmembrane domain. The Notch intracellular domain is then 
translocated into the nucleus, where it acts as a transcriptional activator. 
While signaling mediated by the Delta-like1 ligand and Notch1 blocks B cell differentiation but 
allows T cell development (161, 162), signaling through Notch2 influences the MZB versus FOB 
cell fate within the spleen. Notch2 is highly expressed in mature B cells, and conditional deletion 
of Notch2 results in a decreased number of MZB cells, whereas the FOB and B-1 cell 
compartments developed normally (163). 
In a conditional knockout of the Notch signaling key mediator RBP-J selectively in CD19 
expressing cells only, MZB cells were lost with a concomitant increase in FOB cells, while the B1 
compartment was not affected. (90). These results were further supported by the finding of the 
negative regulator of Notch signaling, Msx2-interacting nuclear target protein (MINT), which 
competes with Notch for the binding to RBP-J and is more abundant in FOB than MZB cells. 
Splenic B cells derived from RAG2-/- chimeric mice reconstituted with MINT-deficient fetal liver 
cells differentiated more efficiently into MZB cells with a concomitant reduction in FOB cells 
(164). 
1.3.6.3.5 BAFF and BAFF-R 
Interactions of the TNF-family member BAFF (B-cell activating factor) with its receptor BAFF-R 
on B cells is crucial for the transition from the T1 to the T2 stage during B cell maturation in the 
spleen and later for mature B cells. 
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Deficiency for either component results in a strong reduction of late transitional (T2, T3) as well as 
mature B cells. In Baff-r-/- mice, MZB cells are hardly detectable. Absence of BAFF prevents the 
development of B-2 B cells beyond the T1 stage such that virtually no mature B cells are formed. 
Interestingly, the B-1 B cell compartment seems not to be affected by this mutation (165-167). 
These findings support the theory that B-1 cells develop independently from B-2 B cells, which 
was already suggested through findings with λ5-/- mice, where B-2 cells develop only to low 
numbers, while B-1 cells reach normal numbers (168). However, it does not absolutely exclude the 
possibility of an activation-dependent generation of B-1 B cells out of the B-2 B cell compartment. 
BAFF over-expression in transgenic mice leads to enlarged T2 and mature B cell compartments 
with B cell hyperplasia and hyperglobulinemia. It is especially the number of MZB cells, which 
become increased, and autoimmunity is manifested through elevated serum autoantibody titers. The 
pathology exhibited by these mice resembles that of the human autoimmune disorder systemic 
lupus erythematosus (SLE), and later in life of the Sjögren’s syndrome (169). In vitro experiments 
showed that BAFF increased survival of immature and mature B cells. Transitional B cells cultured 
in the presence of BAFF also acquired mature B cell markers, indicating that BAFF may also be 
involved in B cell maturation (170). However, the precise mechanism how BAFF/BAFF-R 
mediates survival is not yet fully understood. In vivo and in vitro studies indicated that 
BAFF/BAFF-R signaling is coupled to the Bcl family members of oncogenes. Transgenic 
expression of Bcl-2 in B cells, or the absence of the Bcl-2 antagonist Bim results in phenotypes 
comparable to BAFF-Tg mice and increased Bcl-2 levels were also measured in B cells of BAFF-
Tg mice. Furthermore, introduction of a Bcl-2 transgene into Baff-r-/- mice rescued the 
development of mature B cells and brought the splenic compartment to normal wild type levels 
(166, 169, 171, 172). However, a more recent study suggests that BAFF prevents BCR-induced 
apoptosis not by upregulating Bcl-2 expression but rather through down-regulation of the Bcl-2 
antagonist Bim (173). 
It has also been suggested that BAFF may exert other, non-survival functions. It seems to be 
involved in MZB cell differentiation and may regulate the CD21 and CD23 expression. In contrast 
to the role in B cell survival these functions are independent of Bcl-2  (174, 175). 
Compared to the important role of BAFF and BAFF-R in the transitional B cell compartment for 
the generation of T2 B cells and subsequent stages of B cell maturation, results from genetically 
modified mice for gain and loss of BAFF/BAFF-R did not show any role for these molecules 
during the early B cell development in the bone marrow, nor the survival of immature bone marrow 
or splenic T1 B cells. 
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1.3.6.4 Integrins affecting splenic homing 
MZB cells express higher levels of the integrins LFA-1 and α4β1 than FOB cells. These integrins 
interact with ICAM-1 and VCAM-1. Inhibition of these integrins causes a rapid and selective 
release of B cells from the marginal zone (176). Additionally, MZB cells may be retained in the 
marginal zone by a direct interaction with marginal zone macrophages (MZM) via the Macrophage 
receptor with collagenous structure (MARCO) scavenger receptor on MZMs (177). 
Taken together; in a lymphopenic situation, the proportion of MZB and B-1 cells compared to FOB 
cells is increased suggesting that the system is trying to maintain a first line of defense against 
blood-borne and T-independent antigens through the MZB cells in the spleen and the B-1 cells of 
the body cavities such as the peritoneum and the pleural cavity. The lineage decision is further 
dependent on the signal strength of the BCR and the signals provided by the environment of the 
cell. 
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1.4 Aim of thesis 
Although considerable advance in our understanding of B cell development have been made in 
recent years, still many questions are in debate and new questions have emerged. In this thesis 
some of these questions have been addressed. 
Thus, it is known that during pre-B cell development, successful pairing of a µH chain with the SL 
chain results in surface expression of the pre-BCR and leads to clonal expansion of large pre-B II 
cells. But, since not all cells with a successful pairing expand to the same extent, it was 
investigated whether the quality of the pairing interaction may determine the size of the clonal 
expansion. 
Furthermore, it is known that the interaction of BAFF with BAFF-R is vital for the transition of 
immature to mature B cells. In vivo, the transition from the T1 to T2 stage in the spleen was the 
first stage at which BAFF has been shown to be important, as both BAFF and BAFF-R deficient 
mice show a block at that stage. However, it was not known in detail at which stage during B cell 
development the BAFF-R is first expressed. Using novel monoclonal antibodies specific for mouse 
BAFF-R, we were able to determine the surface expression of this receptor during B cell 
development in the bone marrow. Furthermore, BAFF-R expression was assessed in the context of 
B cell receptor editing and RAG protein expression. 
In a study, testing the potential of TSLP to rescue lymphopoiesis in the absence of IL-7, the 
question was addressed whether B lymphocyte development in IL-7 deficient mice can occur from 
the differentiation of adult BM progenitors in a setting, where TSLP is over-expressed. Using the 
fact that only B cells from adult BM precursors display N nucleotides in the IgH junction of the B 
cell receptor allows distinguishing adult from fetal B cell development. 
Furthermore, a putative new splenic B cell population was characterized. The mature B cell 
compartment in the spleen can be subdivided into CD23+ cells comprising follicular B cells and 
into CD23-/lo cells, which include CD21hi expressing marginal zone B cells. A fraction, which we 
call “newB cells”, of this CD23-/lo cells, however, expresses low levels of CD21. A series of 
experiments, including phenotypic and functional analysis, were designed to characterize these 
cells more closely.  
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Using in vitro stimulation assays it was shown that splenocytes from the different mouse strains 
C57BL/6 and BALB/c responded differently to the mitogen lipopolysaccharide (LPS). 
Additionally, it was known that marginal zone B cells respond faster and more vigorously to LPS 
than follicular B cells. Now, in a series of experiments using sorted splenic B cell subpopulations, 
it was attempted to elucidate why the two mouse strains displayed different responses to LPS.  
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2 MATERIALS AND METHODS 
2.1 General buffers and reagents 
ABI sequencing loading buffer 25 mM EDTA, pH 8.0 
50 mg/ml blue dextran 
in deionized formamide 
ACK buffer (erythrocyte lysis buffer) 0.15 M NH4Cl 
1.0 mM KHCO3 
0.1 mM EDTA 
in H2O, sterile filtered (0.2µm filter) 
DNA loading buffer (6x) 0.25% bromophenol blue 
0.25% xylencyanol 
1 mM EDTA 
30% glycerol 
dNTPs 2.5 mM and 10 mM / nucleotide 
ELISA buffer 4% BSA 
0.2% Tween 20 
5 mM NaN3 
in PBS 
FACS buffer 2% FCS 
5 mM NaN3 
in PBS 
FACS sorting buffer 2% FCS in PBS 
sterile filtered (0.2 µm filter) 
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MACS buffer 2% FCS in PBS 
sterile filtered (0.2 µm filter) 
Oligo(dT) Oligo(dT)12-18 (0.5 µg/µl) 
PCR buffer (10x) 100 mM Tris-HCl, pH 8.3 
500 mM KCl 
15 mM MgCl2 
Protein K solution 10 mM Tris / HCl, pH 8.0 
5 mM EDTA, pH 8.0 
1 % SDS 
300 mM sodium acetate pH 8.0 
add fresh 200 µg/ml Proteinase K 
RNA isolation solution Tri Reagent (MRC, Inc., Cincinnati) 
TAE 40 mM Tris-acetate, pH 8.0 
1 mM EDTA 
TBE (10x) 21.6 g Tris 
11 g boric acid 
8 ml EDTA (0.5M, pH 8.0) 
fill up to 200 ml with ddH2O 
TE 10 mM Tris / HCl, pH 8.0 
1 mM EDTA 
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2.2 Bacterial media and supplements 
LB 10 g tryptone 
5 g yeast extract 
10 g NaCl 
dissolved in 1 l H2O, autoclaved 
LB agar 15 g agar 
10 g tryptone 
5 g yeast extract 
10 g NaCl 
TBS 10 mM MgCl2 
10 mg MgSO4 
10% PEG 4000 
5% DMSO 
15% glycerol 
in LB medium 
sterile filtered (0.2µm filter) 
Ampicillin sodium salt in H2O 
stock 100 mg/ml 
used at 100 µg/ml 
Kanamycin stock 20 mg/ml in H2O 
used at 50 µg/ml 
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2.3 Plasmids 
Vector Insert Application Reference 
pCR2.1 TA-cloning PCR amplificates Subcloning of PCR 
products with TA-
overhang 
Invitrogen 
pELVC PCR amplified 
V(D)J-
rearrangements 
VHDHJH cloning, 
expression of H-
chains in preB cell 
lines 
ten Boekel et al., 1997 (1) 
2.4 Primers for PCR and RT-PCR 
Primer Sequence (5’-3’) Application 
VHJ558 GCG AAG CTT ARG CCT GGG RCT TCA 
GTG AAG 
VHDHJH rearrangement 
VHQ52 GCG AAG CTT CTC ACA GAG CCT GTC 
CAT CAC 
VHDHJH rearrangement 
VH7183 GCG AAG CTT GTG GAG TCT GGG 
GGA GGC TTA 
VHDHJH rearrangement 
VHJ606, S107, X24 GCG AAG CTT WCT GGA GGA GGC 
TTG GTG CAA 
VHDHJH rearrangement 
VHGAM308 GCG AAG CTT GGA GAG ACA GTC 
AAG ATC TCC 
VHDHJH rearrangement 
VHJ558 A.A. #1 (Sal I) TGC GAG GTC GAC CTG CAA CAR TCT 
GGA CCT 
VHDHJH rearrangement 
VHJ558 overlap TGC AAC ART CTG GAC CTG AGC TGG 
TGA AGC CTG GGG CTT CAG 
VHDHJH rearrangement 
VHQ52 A.A. #1 (Sal I) TGC CAG GTC GAC CTG AAG SAG TCA 
GGA CCT 
VHDHJH rearrangement 
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VHQ52 overlap TGA AGS AGT CAG GAC CTG GCC TGG 
TGG CGC CCT CAC AGA GCC TGT CC 
VHDHJH rearrangement 
VH7183 A.A. #1 (Sal I) TGC GAG GTC GAC CTG GTG GAG TCT 
GGG 
VHDHJH rearrangement 
 
VHGAM308 A.A. #1 
(Sal I) 
TCT CAG GTC GAC TTG GTG CAG TCT 
GGA CCT GAG 
VHDHJH rearrangement 
VHGAM308 overlap GTG CAG TCT GGA CCT GAG CTT AAG 
AAG CCT GGA GAG ACA GTC AAG AT 
VHDHJH rearrangement 
leader of SP6 (EcoRI) TGA GAA TTC TGA CTC TAA CCA TGG 
GAT G 
Sequencing of VHDHJH 
rearrangements 
JH2 TGA GGA TGT CTG TCT GCG TCA GCC 
AG 
VHDHJH rearrangement 
JH4 AGG CTC TGA GAT CCC TAG ACA G VHDHJH rearrangement 
JH1A GCA GAG TGT GGC AGA TGG CC VHDHJH rearrangement 
JH2A AGG TGT CCC TAG TCC TTC ATG ACC 
TG 
VHDHJH rearrangement 
JH3A CCA GAC CCA TGT CTC AAC TTT GGG 
AC 
VHDHJH rearrangement 
JH4A GGG TCT AGA CTC TCA GCC GGC TCC 
CTC AGG G 
VHDHJH rearrangement 
JH1,2,4-Cµ (Hind III) TTT GGG AAG CTT TGA CTC TCT GAG 
GAG ACK GTG 
VHDHJH rearrangement 
JH3-Cµ (Hind III) TGG GAA GCT TTG ACT CTC TGC AGA 
GAC AGT GAC CA 
VHDHJH rearrangement 
Cµ (CH1) AGG GGG CTC TCG CAG GAG ACG 
AGG 
Sequencing of VHDHJH 
rearrangements 
RAG-2fwd CAC ATC CAC AAG CAG GAA GTA 
CAC 
RAG-2 transcripts in 
immature B cells 
RAG-2rev GGT TCA GGG ACA TCT CCT ACT AAG RAG-2 transcripts in 
immature B cells 
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mMD1_S GTG GAT TCT GAC TTC TCC GAG MD-1 transcripts in 
FOB cells 
mMD1_AS AGC CAC AGT AGC ACG GTT T MD-1 transcripts in 
FOB cells 
RP105_S AGT CTC CTC CCC ATC TTG TCC RP105 transcripts in 
FOB cells 
RP105_AS GAT AGC GTC ACA TCG GAG AGC RP105 transcripts in 
FOB cells 
mCD14-S317 GCG GAT TCC TAG TCG GAT TC CD14 transcripts in 
FOB cells 
mCD14-AS951 GGT TCC TAT CCA GCC TGT TG CD14 transcripts in 
FOB cells 
5’TLR4 ACA CCA GGA AGC TTG AAT CC TLR4 transcripts in 
FOB cells 
3’TLR4 GCA CTC ATA ATG ATG GCA CC  TLR4 transcripts in 
FOB cells 
5’TLR9 AAG GTC TGG TCA ACC TCT CG TLR9 transcripts in 
FOB cells 
3’TLR9 GAA TGT CAT TGT GTG CCA GG TLR9 transcripts in 
FOB cells 
5_Vlambda1 GGG TAT GCA ACA ATG CGC ATC TTG 
TC 
λ1 light chain 
hypermutations 
3_Vlambda1 CAC GGA CAG GAT CCT AGG ACA 
GTC AGT TTG GT 
λ1 light chain 
hypermutations 
5_Vlambda1_nested GCG AAG AGA AGC TTG TGA CTC 
AGG AAT CTG CA 
λ1 light chain 
hypermutations 
M13/pUC(-40) GTT TTC CCA GTC ACG AC Sequencing 
M13/pUCrev(-24) AAC AGC TAT GAC CAT G Sequencing 
Primers were obtained from Microsynth GmbH, Switzerland or from QIAGEN, Germany. 
Working concentration: 10 µM; restriction sites in italics. 
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2.5 Kits 
Big Dye 1.1 Terminator V 1.1 Cycle Sequencing Kit Applied Biosystems 
Geneclean Kit Q-Biogene 
NucleoSpin Plasmid Kit Macherey-Nagel 
Pure Yield Plasmid Midiprep System Promega 
QIAfilter Plasmid Midi Kit QIAGEN 
QIAprep Spin Miniprep Kit QIAGEN 
QIAquick Gel Extraction Kit QIAGEN 
QIAquick PCR Purification Kit QIAGEN 
Roche Extended PCR kit Roche 
SuperScript First-Strand Synthesis System for RT-PCR Invitrogen 
2.6 Cell culture media and supplements 
SF-IMDM (10 l) 176.6 g IMDM powder 
30.24 g NaHCO3 
100 ml Penicilin Streptomycin Solution 
100 ml MEM Non essential amino acids 
10 ml Insulin [5µg/ml final conc.] 
10 ml 2-mercapto-Ethanol [50µg/ml final conc.] 
30 ml Primatone RL [0.03% final conc.] 
fill up to 10 l with double-quartz dist. H2O (25°C) 
adjust to pH 7.0 (NaOH) 
sterile filtered (0.2µm filter) 
Gibco BRL 
Fluka 
Gibco BRL 
Gibco BRL 
Sigma 
Fluka 
Quest 
 
BrdU 5-bromo-2-deoxyuridine Sigma 
CFSE 5-(and-6)-carboxyfluorescein diacetate, 
succinimidyl ester 
Molecular Probes 
Ciproxin Ciprofloxacinum 0.2g/100ml Bayer 
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CpG CpG1826 
T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*C*
G*T*T (* thiolate modification) 
Microsynth GmbH 
DMEM Dulbecco's Modified Eagle's Medium Gibco BRL 
FCS Fetal calf serum, mycoplasma and virus screened Amimed 
Freezing medium 10% DMSO in FCS  
HAT medium 1 l SF-IMDM medium 
20 ml FCS 
5 ml Ciproxin 
2 x HAT Media Supplement (50x) (Sigma) 
10 ml IL-6 supernatant (in-house) 
sterile filtered (0.2µm filter) 
 
IL-4 Interleukin-4 (IL-4 producing X63 cells) 0.2 mM In-house 
IL-6 Interleukin-6 
IL-6 producing X63 cells (X63-IL6) cultured in 
SF-IMDM 2% FCS medium for 5-7 d, suspension 
sterile filtered through diamotaceous earth 
(Highflow Super Cell Medium, Fluka). Resulting 
supernatant stored at 4°C. 
In-house 
IMDM Iscove’s Modified Dubecco’s Medium Sigma 
Lipofectamine + 
PLUS 
Lipofectamine and PLUS reagents Invitrogene 
LPS Phenol-extracted lipopolysaccharide Sigma 
PBS (10x) 80 g NaCl 
27.1 g Na2HPO4 dihydrate 
2 g KH2PO4 
2 g KCl 
dissolved in 1 l H2O, adjust to pH 7.3 (HCl) 
University Hospital 
Basel 
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PEG 1500 PEG 1500, 50%, sterile solution Boehringer Mannh. 
Puromycin Aminonucleodise antibiotic Gibco BRL 
RPMI ‘Roswell Park Memorial Institute’ Medium Sigma 
Trypsin solution 1x Trypsin-EDTA in HBSS Gibco BRL 
2.7 Bacterial strains 
Host strain Genotype Reference 
E. coli XL2-Blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac 
glnV44 F'[ ::Tn10 proAB+ lacIq Δ(lacZ)M15 
Amy CmR] hsdR17(rK- mK+) 
Stratagene 
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 deoR nupG recA1 araD139 Δ(ara-
leu)7697 galU galK rpsL(StrR) endA1 λ- 
Invitrogen; Grant et 
al., 1990 (2) 
2.8 Mouse strains 
Strain Description Source 
BALB/b H2b In-house 
BALB/c H2d RCC Ltd., Füllinsdorf 
C57BL/6 H2b wild type mice RCC Ltd., Füllinsdorf 
F1 (BALB/c x C57BL/6)  In-house 
F2 BALB/c x (BALB/c x C57BL/6)  In-house 
F2 C57BL/6 x (BALB/c x C57BL/6)  In-house 
BAFF tg transgenic for BAFF gene 
under CMV promoter 
In-house 
Bcl-2 tg transgenic for Bcl-2 gene 
under H2Kb promoter 
Dr. A. Trump, ISREC, 
Lausanne 
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CD40-/- deficient for CD40 In-house 
λ5-/- F216B/B5T+/+F3 Homo, 
deficient for surrogate light 
chain protein λ5 
In-house 
Balb/c MyD88-/- deficient for TLR-signalling 
pathway protein MyD88 
Prof. R. Landmann, 
University Hospital, Basel 
C57BL/6 MyD88-/- deficient for TLR-signalling 
pathway protein MyD88 
Prof. R. Landmann, 
University Hospital, Basel 
B1-8Hi; 3-83κi knock-in mouse for B1-8 HC 
and 3-83 κ-LC 
In-house 
Inbred strains were provided by RCC Ltd. Füllinsdorf. Transgenic, inter- and backcrossed animals 
were bred and kept in the animal facilities of the Biocenter or the Center for Biomedical Research, 
University of Basel, Basel. The MyD88-/- -deficient animals were kindly provided by the group of 
Prof. Regine Landmann, University Hospital, Basel. 
2.9 Cell lines 
Cell line Properties Reference 
40E1 Abelson virus-transformed 
pre-B cell line 
Warner et al., 1979 (3) 
Phoenix-E ecotropic retroviral 
packaging cell line 
Pear et al., 1993 (4) 
Sp2/0 (Sp2/0-Ag14) mouse myeloma 
ATCC CRL-1581 
Shulman et al., 1978 (5) 
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2.10 Antibodies and recombinant proteins 
2.10.1 Antibodies for FACS analysis and sorting 
Antigen (mouse) Clone Provider Reference 
CD4 RM4-5 BD Pharmingen  
CD5 53-7.3 BD Pharmingen Ledbetter et al., 1980 (6) 
CD8 (α-chain) 53-6.7 BD Pharmingen  
CD11b (Mac-I) M1/70 BD Pharmingen Springer et al., 1978 (7) 
CD14 Sa2-8 eBioscience Akashi et al., 2003 (8) 
CD19 1d3 In-house 
BD Pharmingen 
Krop et al., 1996 (9) 
CD21 (CR2/CR1) 7G6 BD Pharmingen Kinoshita et al., 1988 (10) 
CD23 (FcεRII) B3B4 In-house 
BD Pharmingen 
Rao et al., 1987 (11) 
CD24 (HSA) M1/69 BD Biosciences Alterman et al., 1990 (12) 
CD25 (α-chain) 7D4 BD Pharmingen Dantal et al., 1991 (13) 
CD45R (B220) RA3-6B2 BD Pharmingen Coffman et al., 1982 (14) 
CD44 IM7 BD Biosciences Trowbridge et al., 1982 (15) 
CD62L MEL-14 BD Pharmingen Gallatin et al., 1983 (16) 
CD69 H1.2F3 BD Pharmingen Yokoyama et al., 1988 (17) 
CD93 (C1qRp) PB493 In-house Rolink et al., 1998 (18) 
CD117 (c-kit) ACK4 In-house Ogawa et al., 1991 (19) 
IgM M41 In-house Leptin et al., 1985 (20) 
IgM 
(Cµ-chain specific) 
 Jackson Jackson ImmunoResearch 
IgD 1.19 In-house Parkhouse et al., 1992 (21) 
BAFF-R 7A5, B9B In-house Thesis M. Rauch, 2009 
BrdU B44 BD Pharmingen Gratzner et al., 1982 (22) 
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κ-LC 187.1 In-house Yelton et al., 1981 (23) 
λ1+2-LC R26-46 BD Pharmingen  
TLR4 / MD-2 MTS510 eBioscience Akashi et al., 2000 (24) 
CD180 (RP105) RP/14 eBioscience Miyake et al., 1994 (25) 
MD-1 MD113 eBioscience Nagai et al., 2002 (26) 
NK1.1 PK 136 BD Pharmingen Koo et al., 1984 (27) 
In-house produced antibodies were individually titrated before use. Commercial antibodies were 
used at a final dilution of 1:200 (α-BrdU 1:30). 
2.10.2 Secondary and other FACS reagents 
Reagent Dilution Provider 
Streptavidin-PE 1:1000 Southern Biotech 
Streptavidin-APC 1:400 BD Biosciences 
Streptavidin-PE-Cy7 1:400 BD Biosciences 
Propidium iodide 0.2 µg/ml BD Biosciences 
2.10.3 Antibodies for functional assays 
Antigen Clone Properties Provider Reference 
CD3 142-2c11  BD Pharmingen  
CD40 FGK45.5  In-house Rolink et al., 1996 
(28) 
IgM M41 Rat anti-mouse, µ-
chain specific, biotin 
In-house Leptin et al., 1985 
(20) 
IgM  Cµ-chain specific, 
FITC 
Jackson 
ImmunoResearch  
 
κ-LC 187.1  In-house  
MATERIAL AND METHODS  CHAPTER 2   
   
 
44 
rat-IgG   Jackson 
ImmunoResearch 
 
2.10.4 MACS beads 
Antigen Dilution Provider 
B220 1:100 Miltenyi Biotec 
Phycoerythrin (PE) 1:100 Miltenyi Biotec 
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2.11 Molecular biology methods 
2.11.1 Agarose gel electrophoresis of DNA fragments 
Linearized plasmid DNA and DNA fragments were separated for analytical and preparative 
purposes by gel electrophoresis using 0.75% - 1.5% (w/v) agarose gels depending on fragment size 
range in 1 x TAE buffer. For DNA staining the gels contained 0.1µg/ml ethidium bromide. 
Samples were loaded in 6x DNA loading buffer. Electrophoresis was performed at 3-5 V/cm. 
2.11.2 Preparation of chemical-component E. coli strains 
100 ml of LB medium were inoculated with 1 ml of a fresh overnight culture of bacteria. Bacteria 
were grown to early-log phase (OD600 = 0.3 – 0.6) at 37°C shaking. The culture was centrifuged for 
20 minutes (1500 g, 4°C). The bacteria pellet was then resuspended in 10 ml cold, sterile TBS 
medium, aliquoted and immediately shock frozen in liquid nitrogen. Chemical-competent bacteria 
were stored at -80°C. 
2.11.3 Transformation of chemical-competent E.coli strains 
Chemical-competent E. coli bacteria were thawed on ice. For each transformation 100 µl of 
bacteria were mixed with 1 µl of mini-prep plasmid DNA or 1 – 10 µl of ligation reaction and 
incubated for 30 minutes on ice. The heat-shock reaction was done for 90 second at 42°C and 
followed by chilling for 2 minutes on ice. Then 900 µl LB was added and the bacteria incubated for 
1 h at 37°C. Afterwards 100 µl of bacteria were plated on selecting agar plates. After overnight 
growth at 37°C, colonies were picked and expanded in selecting LB medium. Mini-prep DNA was 
prepared and digested with appropriate restriction enzymes to test for correct products. 
2.11.4 Restriction enzyme digestion of DNA 
Restriction enzyme digest was carried out in 10 µl (analytical digests) or in 20 - 50 µl volume 
(preparative digests) with enzyme buffers and conditions recommended by the manufacturer (NEB-
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Biolabs, Sure Roche Diagnostics). Preparative digests were performed for 2 hours and analytical 
digests were done for at least 1 hour. 
2.11.5 Purification of DNA from agarose gels 
Agarose gels were examined under UV light (366 nm) and the bands with size of interest excised. 
UV exposure was kept short do avoid damage to the DNA. Purification was then done with the 
QIAquick Gel Extraction Kit (QIAGEN) according to the manufacturer’s protocol. 
2.11.6 Phosphatase treatment of linearized vector prior to insert ligation 
To prevent self-religation of linearized vectors, the plasmid DNA was treated with 1 U of calf 
intestine alkaline phosphatase for 30 minutes at 37°C to remove 5’ phosphates. The alkaline 
phosphatase was inactivated by heating the reaction mix to 75°C for 10 minutes and removed by 
gel electrophoresis and thereby the dephosphorylated vector was gel-purified. 
2.11.7 DNA ethanol precipitation 
Plasmid and genomic DNA were precipitated by adding 1/10 volume 3 M sodium acetate (ph 4.8) 
and 2 volumes of 100% ethanol. The mixed DNA solution was then incubated for 20 minutes at -
20 °C followed by 15 minutes centrifugation (21’000 g, 4°C). The precipitated DNA was then 
washed with ice-cold 70% ethanol and air-dried. DNA was dissolved in 1 x TE buffer. 
2.11.8 Ligation of DNA fragments into vectors 
2.11.8.1 Restriction enzyme fragments 
Ligation of restriction enzyme fragments with cohesive ends were performed at a molecular ratio 
between vector and insert of 1:2-4 in a volume of 20 µl using 1 µl of T4 DNA ligase (400U/µl). 
The reaction was done overnight at 16°C. 1 -10 µl of the ligation reaction was used to transform 
chemical-competent bacteria. 
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2.11.8.2 PCR fragments 
PCR fragments amplified by use of the Taq DNA polymerase were directly cloned into the 
pCR2.1-Vector or TOPO-TA vector (TA Cloning kit, TOPO-TA Cloning kit, Invitrogen) 
according to the manufacturer’s protocol. 
2.11.9 DNA phenol-chloroform extraction 
To remove protein and other impurities from DNA a phenol-chloroform extraction was performed. 
For this 1 volume pure phenol (TE saturated) was added, the sample mixed and spun for 10 
minutes (21’000 g, 4°C). The DNA-containing water-phase was transferred into a new tube and 
extracted with 1 volume of 1:1 mixture of phenol and chloroform followed by a chloroform 
extraction at conditions as in the phenol extraction step. The DNA was precipitated by adding 1/10 
volume 3 M sodium acetate (pH 4.8) and 1 volume isopropanol and let incubate at -20°C for 20 
minutes followed by centrifugation for 20 minutes (21’000 g, 4°C). The precipitated DNA was 
then washed with ice-cold 70% ethanol and air-dried. DNA was dissolved in 1 x TE buffer. 
2.11.10 Polymerase chain reaction (PCR) 
2.11.10.1 Analytical PCR 
For analytical purposes, PCR reactions were carried out with Taq DNA polymerase based on the 
following standard protocol: 
PCR reaction mix: 
1-5 µl DNA template 
1 µl forward primer 
1 µl reverse primer 
2 µl 10x PCR buffer 
3 µl dNTPs (2.5 mM stock conc.) 
0.5 µl Taq DNA polymerase 
filled up to 20 µl with ddH2O 
 
 
MATERIAL AND METHODS  CHAPTER 2   
   
 
48 
PCR program: 
initial denaturation 94°C 90”  
    
denaturation 94°C 30”  
annealing Tm-3°C 30” 38 cycles 
elongation 72°C 1 min/kb  
    
final elongation 72°C 10’  
(Tm: primer melting temperature) 
2.11.10.2 PCR for the amplification of VJ558HDHJH- and V7183HDHJH rearrangements 
VHDHJH-rearrangements were amplified from purified genomic DNA of immature and mature B 
cells by a 2-step PCR strategy. In the first round of amplification a VH-family specific primer was 
used together with a 3’ primer hybridizing immediately downstream to a JH gene element. In the 
second round of amplification the PCR product was elongated at the 5’ end with a second VH-
family-specific primer including a SalI restriction site and a nested 3’ primer containing the 
beginning of the Cµ gene element including a silent HindIII restriction site in the third and fourth 
codons of the Cµ region. 
1. round PCR: 
Primers: 
forward: VHJ558 or VH7183 
reverse: JH2 
 
PCR reaction mix: 
1 µl DNA template (purified by phenol-chloroform extraction) 
1 µl 5’ primer 
1 µl 3’ primer 
3 µl 10x Reaction buffer 1 (Roche Extended PCR kit) 
6 µl dNTPs (2.5 mM stock conc.) 
0.5 µl DNA Polymerase mix (Roche Extended PCR kit) 
filled up to 30 µl with ddH2O 
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PCR program: 
initial denaturation 94°C 90”  
    
denaturation 94°C 30”  
annealing 65°C 30” 38 cycles 
elongation 68°C 2’  
    
final elongation 68°C 10’  
2. round PCR: 
Primers: 
forward: VHJ558 A.A. #1 (Sal I) + VHJ558 overlap  ratio 10:1 or  
VH7183 A.A. #1 (Sal I) 
reverse: JH1,2,4-Cµ (Hind III) 
 
PCR reaction mix: 
1 µl DNA template (gel-purified from 1. round PCR) 
1 µl 5’ primer 
1 µl 3’ primer 
5 µl 10x Reaction buffer 1 (Roche Extended PCR kit) 
7 µl dNTPs (2.5 mM) 
0.75 µl DNA Polymerase mix (Roche Extended PCR kit) 
filled up to 50 µl with ddH2O 
 
PCR program: 
initial denaturation 94°C 60”  
    
denaturation 94°C 30”  
annealing 50°C 30” 5 cycles 
elongation 68°C 45”  
    
denaturation 94°C 30”  
annealing 55°C 30” 10 cycles 
elongation 68°C 45”  
    
denaturation 94°C 30”  
annealing 60°C 30” 20 cycles 
elongation 68°C 45”  
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2.11.10.3 PCR for the amplification of λ1 light chain-rearrangements 
λ1 light chain-rearrangements were amplified from genomic DNA of sorted cells by a semi-nested 
PCR as described by Jacobs et al. (29). 
1. round PCR: 
Primers: 
forward: 5’_Vλ1 
reverse: 3’_Jλ1 
 
PCR reaction mix: 
1 µl genomic DNA 
1 µl 5’ primer 
1 µl 3’ primer 
3 µl 10x PCR buffer 
5 µl dNTPs (2.5 mM) 
0.5 µl Taq DNA Polymerase 
filled up to 30 µl with ddH2O 
 
PCR program: 
initial denaturation 95°C 2’  
 88°C 3’  
 60°C 2’  
 72°C 2’  
    
denaturation 94°C 1’  
annealing 60°C 1’ 29 cycles 
elongation 72°C 1’30”  
    
final elongation 72°C 10’  
2. round PCR: 
Primers: 
forward: 5’_Vλ1_nested 
reverse: 3’_Vλ1 
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PCR reaction mix: 
1 µl Template DNA (gel-purified from 1. round PCR) 
1 µl 5’ primer 
1 µl 3’ primer 
3 µl 10x PCR buffer 
5 µl dNTPs (2.5 mM) 
0.5 µl Taq DNA Polymerase 
filled up to 30 µl with ddH2O 
 
PCR program: 
initial denaturation 92°C 1’  
    
denaturation 92°C 1’  
annealing 63°C 1’ 40 cycles 
elongation 72°C 1’30”  
    
final elongation 72°C 10’  
2.11.11 Sequencing of plasmid DNA 
Sequencing of plasmid DNA was performed by dye-terminator sequencing on an automated gel 
electrophoresis sequencer (ABI PRISM 377 DNA Sequencer). 
The sequencing gel was prepared by dissolving 18 g urea and 7.5 ml Acrylamid/Bis (30%, 37.5:1) 
in 23 ml ddH2O. The gel mix was then de-ionized by adding a spoon of amberlite and stirring it for 
20 min at RT. 200 ml of freshly prepared 10x TBE buffer were sterile filtered (22 µm filter). The 
gel mix was filtered through the same filter, and 6 ml of the 10x TBE buffer were added. The gel 
mix was then degassed for 5 min and cooled on ice. The glass plates of the sequencer were washed 
with Biorad cleaning solution and rinsed with a 9:1 isopropanol-water mixture. The readily cleaned 
glass plates were assembled with 0.2 mm spacers defining the pouring chamber. The 
polymerization of the gel was initiated by adding 200 µl APS (10%) and 20 µl TEMED to the gel 
mix. Immediately afterwards, the gel was poured. Polymerisation was allowed for 2 h at RT. 
Subsequently, the gel was mounted into the sequencer and the rest of the 10x TBE buffer diluted to 
1x TBE and added to the corresponding tanks of the sequencer as running buffer. 
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The necessary sequencing product was obtained by PCR from sample DNA incorporating 
fluorescent terminator dideoxynucleotides (Big Dye, Perkin-Elmer). The reaction was performed 
according to the following standard protocol: 
Sequencing reaction mix: 
3 µl Sample DNA (0.5-1 µg, mini-prep) 
0.35 µl primer (3.5 pmol/µl) 
4 µl Big Dye sequencing mix 
filled up to 20 µl with ddH2O 
 
Sequencing reaction standard program: 
initial denaturation 96°C 1’  
    
denaturation 96°C 30”  
annealing 50°C 20” 35 cycles 
elongation 60°C 4’  
    
final elongation 60°C 5’  
The samples were precipitated by adding 2 µl 3 M sodium acetate and 50 µl 100% ethanol. After 
incubation at RT for 20 minutes, the samples were centrifuged for 20 minutes (21’000 g, RT). The 
precipitate was washed with 150µl 70% ethanol, centrifuged, dried for 5 minutes in a Speed-Vac at 
RT and resuspended in 3.5 µl ABI loading buffer. Prior to loading on the gel, the samples were 
denatured at 95°C for 3 minutes. 1 µl of each sample was loaded on the gel. Sequencing runs were 
done for 10 h at 2400 V. Sequence readout was performed using the ABI PRISM 377XL Data 
Collection software (version 2.6). 
2.11.12 Isolation of genomic DNA 
2.11.12.1 <100’000 cells / sample 
Cells were resuspended in 50 µl PBS, snap freezed and stored at -70°C prior to genomic DNA 
preparation. The frozen cells were heated for 1 minute to 68°C and immediately chilled on ice. 
Then 5 µl proteinase K (10 µg/µl) were added and the cells incubated for 2 hours at 55°C followed 
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by a heat-inactivation of the proteinase K for 10 minutes at 94°C. The lysate was directly used for 
PCR or stored at -20°C. 
2.11.12.2 >100’000 cells / sample 
Cells were incubated in 400 µl of proteinase K solution overnight at 55°C shaking. To remove 
protein and other impurities from DNA a phenol-chloroform extraction was performed. 400 µl pure 
Phenol (TE saturated) was added to the cell lysate, the sample mixed and spun for 10 minutes 
(21’000 g, 4°C). The DNA-containing water-phase was transferred into a new tube and extracted 
with 200 µl phenol and 200 µl chloroform followed by an extraction with 400 µl chloroform at 
conditions as in the phenol extraction step. The DNA was precipitated by adding 400 µl 
isopropanol and let incubate at -20°C for 20 minutes followed by centrifugation for 20 minutes 
(21’000 g, 4°C). The precipitated DNA was then washed with ice-cold 70% ethanol and air-dried. 
DNA was dissolved in 50 µl 1 x TE buffer for 30 minutes at 55°C. 
2.11.13 Isolation of total RNA 
Sorted cells up to 3 x 106 cells where resuspended in 500 µl Trizol and incubated for 5 minutes at 
RT. Then 100 µl CHCl3 were added, the sample vigorously shaken during 15 seconds and let stand 
for 10 minutes at RT. After centrifugation for 15 minutes (12000 g, 4°C) the aequous phase was 
transferred into a fresh tube. Then 1 µl of linearized polyacrylamide and 250 µl isopropanol were 
added and let the total RNA precipitate for 10 minutes. After that the sample was centrifuged for 8 
minutes (12000g, 4°C), the pellet washed with 500 µl 75% ethanol, again centrifuged for 5 minutes 
(12000 g, 4°C). Finally, the pellet was air-dryed for 5 minutes and resuspended in 10 µl DEPC-
treated ddH2O. The RNA was stored at -80°C.  
2.11.14 cDNA by reverse transcription for semi-quantitative PCR 
Normally, half of the isolated RNA was used for reverse transcription. The reverse transcription 
reaction mix was incubated for 30 minutes at 37°C and then the RQ DNase 1 was inactivated for 
10 minutes at 65°C. Before adding the reverse transcriptase, the sample was quickly chilled on ice 
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and 20 µl removed for a negative control. For the reverse transcription 0.5 µl RNase OUT and 1 µl 
Superscript II reverse transcriptase (200U/µl) were added. 
Reverse transcription reaction mix: 
5 µl RNA in DEPC-treated ddH2O 
6 µl 10 x reverse transcriptase buffer 
12 µl MgCl2 (25 mM) 
4 µl dNTPs (10 mM) 
4 µl DTT (0.1 M) 
2 µl Oligo(dT)12-18 (0.5 µg/µl) 
0.4 µl random hexamers (50 ng/µl) 
2 µl RQ DNase 1 
21.6 µl DEPC-treated ddH2O 
 
Reverse transcription reaction: 
Add 1 µl Superscript II reverse transcriptase (200 U/µl) and 0.5 µl RNase OUT 
25°C 8’  
65°C 1h 30’  
70°C 15’  
The cDNA was stored at -20°C. The cDNA was tested in a PCR reaction for β-actin transcripts and 
the negative control was used to test for the absence of genomic DNA contaminations. 
2.12 Cell culture 
2.12.1 Cryopreservation of cells 
For cryopreservation pelleted cells were resuspended in cold (+4°C) freezing medium at a cell 
density dependent on the cells. 1 ml aliquots in 2 ml cryotubes (Nunc) were cooled down on ice 
and incubated at -80°C for >12 h. For longterm storage the aliquots were stored in a liquid nitrogen 
tank. 
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For thawing, cells were warmed up in a 37°C water bath or at RT and transferred immediately to 
10 ml of the appropriate cell culture medium. After centrifugation at 1200 rpm at 4°C for 10 min, 
the cells were gently resuspended in the appropriate cell culture medium and transferred into a 
tissue culture dish. 
2.12.2 Determination of cell numbers 
Cell numbers were determined by manually counting cells in an improved Neubauer 
haemocytometer with 0.1 mm depth. An aliquot of the cell suspension was diluted 1:5-1:10 in 
trypan blue solution and loaded into the chamber. Cells in at least two of the outer squares, 
consisting of 16 small squares each, were counted. Debris and dead cell were excluded by the 
trypan blue dye. The cell number per ml was calculated from the average cell number in an outer 
square times 104. 
2.12.3 Isolation of mouse bone marrow cells 
Bone marrow cells were collected from femur and tibea. Bones were separated from muscle tissue 
and opened on both ends followed by flushing out the bone marrow with cell culture medium and a 
siringe with a 27G needle. Cell suspensions were achieved by carefully pipetting the flushed out 
marrow up and down. 
2.12.4 Lysis of red blood cells 
Cell suspensions containing erythrocytes were centrifuged for 10 minutes at 250 g, 4°C. Cells were 
resuspended in 1-2 ml ACK buffer and incubated for 1-2 minutes at RT. The lysis reaction was 
stopped by adding 10 ml cell culture medium to the cells. After that the cells were centrifuged 
again and then resuspended in cell culture medium. 
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2.12.5 Surface staining of cells for FACS analysis 
Normally cell suspensions of 10-20 x 106 cells/ml were prepared. The antibodies used were either 
directly labeled with a fluorescent dye or the antibodies were biotinylated and revealed by a 
fluorescent dye-labeled streptavidin reagent. The appropriate antibody dilutions had been titrated 
on appropriate cells beforehand. Commercial antibodies were mostly used at a final dilution of 
1:200 in FACS buffer for FACS analysis or in cell culture media or Sorting buffer, respectively, for 
FACS sorting. 
For analytical staining 50 µl of cell suspensions were mixed with 50 µl of prediluted antibodies in 
FACS buffer in U-bottom 96-well plates. The cell suspensions were incubated for at least 30 
minutes on ice or at 4°C, protected from light. After the incubation the cells were washed with 
FACS buffer, resuspended in 200 µ l FACS buffer and analysed on a FACS Calibur (BD 
Biosciences). If possible (FL3 not used for staining) dead cells were excluded from the analysis 
using propidium iodide [0.2 µg/ml]. The collected data was either analysed in CellQuest Pro v3.4 
(BD Biosciences) or in FlowJo v6.4 (Tree Star) software. 
For preparative cell sorts fluorescent dye-coupled or biotinylated antibodies were directly diluted in 
single cell suspensions. Sorting was performed on a 2-Laser FACS Aria cell sorter with FACSDiva 
Software (BD Biosciences). 
2.12.6 Surface staining for pre-BCR expression on 40E1 cells (pairing assay) 
Due to the relatively low density of pre-BCR expression on the cell surface a FACS staining was 
established using an amplifying staining protocol by means of α-IgMbio (1:800) in combination 
with the anti-isotype antibody mouse-α-rat IgGbio (1:800) and strep-PE (1:1000). Incubation and 
washes were otherwise done as for normal surface stainings. Dead cells were excluded from the 
analysis using propidium iodide [0.2 µg/ml]. 
2.12.7 Intracellular staining of cells for FACS analysis 
1-2 x 106 cells were fixed in 600 µl of 2% paraformaldehyde in 1xPBS for 30 minutes at 4°C. After 
fixation the cells were washed twice with 1xPBS (centrifugation 10 minutes at 290 g) and 
resuspended in 200 µl FACS buffer + 2% saponin. The cells were distributed in half and to one 
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tube directly labeled antibody in FACS buffer + 2% saponin added (final conc.: 1:200 in 200 µl). 
After incubation for 45 minutes at 4°C the cells were washed once with FACS buffer + 0.2% 
saponin and once with FACS buffer, resuspended in 200 µl FACS buffer and analysed on a FACS 
Calibur (BD Biosciences). 
2.12.8 Purification of newB cells from mouse spleens 
Single cell suspensions from spleens were made. After erythrocyte-lysis splenocytes were stained 
with α-NK1.1PE, α-CD93bio and α-CD5PE for 30’ at 4°C. Cells were washed and resuspended in 
FACS-sort buffer and incubated 15’ at 4°C with streptavidin-coupled phyco-erythrin (strep-PE 
1:2000). Again the cells were washed and resuspended in FACS-sort buffer with anti-PE MACS 
beads (final conc.: 1:10) and incubated for 45’ at 4°C. After washing the cells were resuspended in 
FACS-sort buffer, filtered and loaded twice on pre-equilibrated MACS columns (model LS). The 
columns were washed with FACS-sort buffer and the total efflux collected and stained with α-
B220PE-Cy7, α-CD21FITC and α-CD23PE for 30’ at 4°C. After washing and resuspending in FACS-
sort buffer the cells were ready to be sorted by FACS. NewB cells were sorted as B220+ CD21-/low 
CD23-/low cells. 
2.12.9 Ca2+ flux measurement 
Single cell suspensions from spleens were made. After erythrocyte-lysis the cells were resuspended 
in IMDM+2% FCS to 1 x 107 cells/ml. Then the cells were loaded with 5 µg/ml of the Ca2+-
sensitive Indo-1 dye for 45 minutes at 37°C. After the Indo-1 loading the cells were stained in 
IMDM+2% FCS with fluorescent dye-labeled antibodies for surface markers for 45 minutes on ice. 
For labeling with fluorescent dye-labeled streptavidin reagent the cells were washed and labeled in 
D-PBS (CaCl2 / MgCl2). After the surface labeling the cells were resuspended in 1 ml IMDM+2% 
FCS. The Ca2+ flux measurement was done on a 4-Laser FACS LSRII (BD Biosciences). After 
establishing of the baseline fluorescence, cells were triggered with 50 µg/ml α-IgM (µ-chain 
specific) or 7.5 µg/ml α-CD3 (clone 2c11). As a positive control of Indo-1-loading cells were 
triggered with 5 µg/ml of the ionophore ionomycin. 
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2.12.10 Intracellular anti-BrdU staining 
Cells sorted for the appropriate surface phenotype were fixed ON in 70% ethanol at 4°C. After the 
fixation the cells were washed 3 times in 1xPBS (centrifugation 6 minutes at 2500 g) and then 
resuspended in 500 µl 3 M HCl 0.5% Tween20 for 20 minutes at RT. Then the cells were spun 
down (6 minutes at 2500 g) and resuspended in neutralizing 250 µl 0.01 M sodium tetraborat for 3 
minutes at RT. After two washes with 1xPBS 0.5% Tween20 (6 minutes at 2500 g) the cells were 
resuspended in 200 µl with 1xPBS 0.5% Tween20, distributed in half and to one tube α-BrdU-
FITC antibody added (final conc.: 1:10). After incubation for 20 minutes at 4°C the cells were 
washed with 1xPBS (6 minutes 2500 g) and resuspended in 250 µl PBS for FACS analysis. 
2.12.11 In vitro CFSE-labeling of sorted cells 
Sorted cells from bone marrow or spleen were washed with 1xPBS to get rid of proteins and 
resuspended in 500 µl PBS with CFSE (Carboxyfluorescein succinimidyl ester). The cells were 
incubated for 10 minutes at RT and then washed with cell culture medium. After that the cells were 
resuspended in cell culture medium at the appropriate concentration and used for in vitro cell 
culture assays. At the end of the assay the cells were analysed on a FACS Calibur or sorted on a 
FACS Aria cell sorter (BD Biosciences). 
2.12.12 Transfection and transduction 
2.12.12.1 Transfection of packaging cell line Phoenix-E  
Cells of the packaging cell line Phoenix-E were seeded at 2.5 x 105 cell/6-well in RPMI + 10% 
FCS and incubated at 37°C 5% CO2 for two days before the transfection (semi-confluent). For the 
transfection, 2µg of plasmid DNA with 10 µl PLUS reagent and 100 µl DMEM medium were 
mixed and incubated for 15 minutes at RT and then 2.5 µl Lipofectamine and 100 µl DMEM 
medium were added, mixed and incubated for further 15 minutes. Immediately before the 
transfection the cells were washed twice with serum-free DMEM medium and kept in 1 ml serum-
free DMEM medium. Then the transfection mix was drop-wise added to the cells. The cells were 
incubated with the transfection mix for 5–6 hours at 37°C 10% CO2. After that, the supernatant was 
replaced with 3 ml complete RPMI medium with 10% FCS and incubated for 24 hours at 37°C 5% 
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CO2. To remove incomplete viral particles, which are generated within the first hours after the 
transfection, the supernatant was carefully aspirated and replaced with fresh 3 ml complete RPMI + 
10% FCS and the cultures incubated for a further 24 hours at 37°C 5% CO2. The supernatant was 
finally collected and used for the retroviral transduction of the pre-B cell line 40E1 by spin-
infection. 
2.12.12.2 Retroviral transduction of the pre-B cell line 40E1 by spin-infection 
Collected virus-containing supernatant was shortly spun down in order to remove cell debris. Semi-
confluent cells of the pre-B cell line were harvested and counted. 5 x 104 cells were transfered into 
2 ml Eppendorf-tubes and 1 ml retroviral supernatant added. The spin-infection was then carried 
out in a table-top Eppendorf centrifuge for 3–4 hours at 1160 g and 30°C. After that, the 
supernatant was carefully aspirated and the cells plated in 2 ml SF-IMDM + 2% FCS in a 6-well 
plate. The cells were incubated at 37°C 10% CO2 for 1-2 days. Then the cells were selected for 
successful transduction in 6 ml cultures with 2 µg/ml puromycin and expanded. 
2.12.13 In vitro proliferation assays 
Cells sorted for the appropriate surface phenotype were cultured in flat-bottom 96-well plates at 1 x 
105 cells/well in SF-IMDM + 2% FCS. The cultures were supplemented either with a single 
stimulus or a combination of 25 µg/ml α-IgM (M41), 20 µg/ml α-CD40 (clone FGK45.5), 20 µM 
IL-4 (clone X63), 1-50 µg LPS (phenol-extracted) and 0.5 µg/ml CpG (CpG1826). After 63 hours 
cultures were pulsed with 1 µCi [3H]thymidine for 9 hours before the cells were harvested onto 
Filtermat A filters and analyzed either on a BetaPlate 1205 or Microbeta Trilux scintillation 
counter (Perkin Elmer). 
2.12.14 Hybridoma from sorted splenic B cells 
Sorted FOB (CD19+ CD93- CD21+ CD23+), MZB (CD19+ CD93- CD21hi CD23-/lo) or newB 
(CD19+ CD93- CD21-/lo CD23-/lo CD5-) cells were cultured under activating conditions (5x105 
cells/24-well in 1 ml SF- IMDM + 2%FCS and 10µg/ml LPS) for 3 days. Then the cultures were 
washed twice with SF-DMEM and transferred into 50 ml tubes. In parallel, in log-phase growing 
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Sp2/0 cells were harvested by centrifugation at 1200 rpm and 4°C for 10 min and then washed 
twice with SF-DMEM. Then 2x106 Sp2/0 cells were added to the FOB, MZB or newB cells, and 
centrifuged again. After careful and complete removal of the supernatant the tube was shaken in a 
37°C water bath, while 1 ml of pre-warmed 50% PEG solution was added drop-wise during 1 min 
to the cell pellet. The dissolved pellet was shaken for 1 min at 37°C, and then 10 ml of pre-
warmed, alkaline SF-DMEM were added drop-wise to the cells while shaking the tube. 
Subsequently, the cell suspension was centrifuged at 800 rpm at RT for 5 min. The cell pellet was 
resuspended carefully in 5000 ml pre-warmed HAT medium and plated out into 96-well F-bottom 
plates (200 µl/well). Cultures were incubated at 37°C for 10-14 days until cell clusters were visible 
by the naked eye. Clones tested positively for Ig production in ELISA were sub-cloned, its 
supernatants harvested and cells frozen. 
2.13 Animal work 
2.13.1 In vivo labeling of proliferating cells with BrdU in mice 
Initially, adult mice received an intraperitoneal injection of 1.0 mg of the thymidine analog BrdU in 
1xPBS. In addition, mice received 1.0 mg/ml BrdU in the drinking water, which was exchanged 
every 3 days with a fresh preparation during the time of labeling (pulse). The BrdU-containing 
drinking-water bottles were shielded with aluminum foil to prevent light-mediated degradation of 
the BrdU. At the end of the experiment cell suspensions were prepared from lymphoid organs and 
stained for intracellular BrdU. 
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3 ANALYSES OF THE PRE-BCR QUALITY IN PRE-B I 
CELLS WITH DIFFERENT PROLIFERATIVE 
CAPACITIES 
3.1 Introduction 
The maturation of B cells from B lineage-committed progenitors starts in the fetal liver during 
perinatal life and continues in the bone marrow after birth. Antigen-sensitive, immature B cells 
leave these primary lymphoid organs, migrating to the spleen, where further development forms the 
mature B cell pool. Along this pathway, checkpoints exist to assure the development of competent, 
B cell receptor (BCR)-expressing B cells. This pathway can be characterized by various changes in 
intracellular and surface-expressed molecular markers (1). At the pre-B I cell stage, cells start to 
rearrange a VH chain gene element to the already rearranged DHJH segments, thus, finalizing the 
rearrangement of a complete µH chain. When the rearrangement is in-frame, the cells start to 
express the µH chain protein in the cytoplasm (cµ+). However, producing a µH chain protein is not 
sufficient for the further development of the pre-B cell into later stages of more mature B cells. In 
approximately 25% of the pre-B cells, the µH chain is expressed together with the surrogate light 
(SL) chain at the cell surface as a pre-BCR. This surface expression is dependent on a pairing 
interaction of the µH chain with the VpreB- and λ5-components of the SL chain and, hence, 
establishes an important checkpoint in pre-B cell development. In addition, this pairing interaction 
seems to be involved in maintaining IgH allelic exclusion. It could be shown for the few pre-B II 
cells that productively rearrange both IgH alleles, that only one of the two µH chain proteins is 
pairing with the SL chain and gives rise to a pre-BCR (2). Successful pairing leads to the clonal 
expansion of these cells through 2-5 rounds of division. Mutations affecting the pairing between 
the µH chain and the SL chain or absence of one of the SL chain components abrogate the clonal 
expansion and therefore lead to much reduced output of B cells from the bone marrow and, hence, 
resulting in B lymphopenia (3). 
Pre-B I cells cultured on stromal cells together with IL-7 prevents the cells from further 
differentiation and they can be cultured for extended times with a cell cycle time of 18 hours. 
Withdrawal of IL-7 results in the arrest of the cell cycle in early G1 and induces differentiation to 
surface Ig-expressing (sIg+) immature B cells (4). 
Pre-B I cells isolated from bone marrow of wild-type mice may be cultured, for a limited time, in 
the absence of stromal cell support or any added cytokines. These in vitro bulk cultures of pre-B I 
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cells show proliferation and differentiation into sIg+ immature B cells. However, pre-B I cells of 
SL chain-deficient λ5-/- mice do not show that proliferative expansion. As the proliferation of pre-B 
I cells depends on pre-BCR expression it could still be argued, that a ligand is required to trigger 
signaling through the pre-BCR resulting in proliferation. This ligand could for example, be 
provided by a neighboring cell. To limit this possibility, ex vivo isolated single pre-B I cells were 
cultured in the absence of stromal cells and cytokines. Still, these cells were able to proliferate with 
a frequency and efficiency similar to pre-B I cells in bulk cultures (5). 
However, of the 15% ex vivo isolated pre-B I cells, which go through a clonal expansion, not all of 
them proliferate to the same extent, giving rise to clones of different size of 4, 8, 16, 32 and 64 
cells (2-5 rounds of cell division). Taking into account that these cells proliferate in the absence of 
any cytokine, other ligand or cell-cell contact, and that SL chain-deficient pre-B I cells do not show 
this clonal expansion, it is, therefore, possible that the “fitness” of the pre-BCR complex itself 
plays a major role in this proliferative expansion. We define this “fitness” as the avidity of any 
given µH chain in its pairing with the invariant SL chain and, therefore, its cell surface expression 
as a pre-BCR. According to this hypothesis, well pairing µH-SL complexes would give rise to 
larger clones and loosely pairing to smaller clones, while a non-pairing µH chain abrogates clonal 
expansion and can block the further development of the pre-B cell (4, 5). 
 
The aim of this study is to verify the hypothesis, that the avidity of a given µH chain to pair with 
the SL chain can determine the efficiency by which pre-B I cells go through a proliferative burst. 
To that end, we isolated pre-B I cells from bone marrow of mice, labeled them with CFSE and 
cultured them in the absence of stromal cell support and any added cytokines. After 5 days of 
culture, cells were isolated according to their proliferative history. The µH chain gene 
rearrangements were cloned and sequenced and used in an in vitro pairing assay to test the ability 
of individual µH chains to pair with the SL chain and consequently being expressed as a pre-BCR 
on the cell surface.  
Finally, the efficiency of cell surface expression of these individually cloned µ H chains were 
compared to the proliferative history of the cells, from which they were derived. Thus, we would 
test for a correlation between the efficiency of the pre-B cell to proliferate and the “fitness” of the 
pre-BCR. 
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3.2 Results 
3.2.1 In vitro proliferation of sorted pre-B I cells in absence of stromal cell 
layer and cytokines 
Pre-B I cells (B220+ c-kit+ CD19+) were isolated by FACS from bone marrow (BM) of young (3 
weeks old) C57BL/6 mice (5). The sorted pre-B I cells were labeled with carboxyfluorescein 
succinimidyl ester (CFSE) to monitor the proliferative expansion during the in vitro culture in 
normal tissue culture medium (SF-IMDM + 2% FCS) without stromal cell support and any added 
cytokines. 
After 5 days, cultured cells were analysed by FACS for CFSE fluorescence intensity. The data 
indicate, that the initially seeded cells have undergone proliferation to different extent. According 
to the CFSE-profile, the cells segregated into roughly four major populations, which allowed 
sorting four subpopulation of cells comprising of (non-) or low, lower-intermediate, higher-
intermediate or highly proliferated cells (Figure 1). 
 
Figure 1. Proliferative expansion of in vitro cultured pre-B I cells. 
Sorted pre-B I cells from bone marrow of young (3 weeks) C57BL/6 mice were labeled with the fluorescent 
dye CFSE and cultured in vitro for 5 d. Subsequently cells were sorted according to their CFSE content 
separating them into four subpopulations of cells, which have undergone increasing rounds of division. 
3.2.2 Isolation and cloning of VHDHJH-rearrangements from low to highly 
proliferated pre-B cells 
VHDHJH-rearrangements were isolated from each pool of cells sorted according to their CFSE 
content using a VH gene family-specific PCR. The PCR utilized 5’ primers specific for sequences 
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of the proximal VH7183 and distal VHJ558 VH gene families, which together represent the majority 
of VH gene elements expressed in the BM (6). These primers were combined with a 3’ primer 
representing sequences downstream of the JH2 (Figure 2) limiting the isolation and cloning to 
VHDHJH-rearrangements containing the JH2 gene element. 
 
Figure 2. Genomic PCR for the isolation of rearranged VHDHJH genes. 
PCR strategy for the amplification of VHDHJH-rearrangements containing (top) a VH7183 gene element or a 
VHJ558 gene element (bottom). 
The PCR products with the correct size for either VH7183DHJH2 or VHJ558DHJH2 rearrangements 
were cloned into the retroviral expression vector pELVC, thus generating VH7183 and VHJ558 
gene family-specific libraries of VHDHJH-rearrangements for each sorted population. The retroviral 
expression vector pELVC allows the expression of each cloned productive VHDHJH-rearrangement 
in a pre-B cell line to test the cytoplasmic and surface expression capabilities of the isolated heavy 
chain. The pELVC vector contains the leader (L) exon/intron sequence of the SP6 µ gene and the 
membrane form of the µH chain constant-region (Cµm). Particular VHDHJH-rearranged fragments 
were cloned into the expression cassette using the restriction sites SalI in the framework-region 1 
of VH and the silent HindIII site in the third and fourth codons of the constant region. Both 
restriction sites were introduced during the second PCR amplification step (Figure 2 and Methods). 
The expression of the cloned µH chain is controlled by the µ -core enhancer (Eµ-core), which is 
located upstream of the leader sequence (Figure 3) (6, 7). 
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Figure 3. pELVC vector. 
Part of the vector that contains the leader (L) of the SP6 µ  gene (7), a VHDHJH-rearrangement, followed by 
the membrane form of the µH chain constant-region (Cµm). Expression is under the control of the µ -core 
enhancer (Eµ-core) located upstream of the leader sequence. 
Cloned VHDHJH-rearrangements obtained from each sorted pre-B cell population and representing 
both the VH7183 and the VHJ558 gene families were fully sequenced. The obtained sequences were 
analysed for productive, in-frame rearrangements. Furthermore, the VH gene family members were 
determined and the junction defining the CDR3 region was analysed. From a total of 71 unique 
VHDHJH-rearrangements sequenced, 31 productive VHDHJH-rearrangements were obtained. 
 
Figure 4. Protein sequences of isolated, in-frame (A) VH7183DHJH2 or (B,C) VHJ558DHJH2 
rearrangements with junctional analysis. 
For panels B, C and description see next page. 
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Figure 4. Protein sequences of isolated, in-frame (A) VH7183DHJH2 or (B,C) VHJ558DHJH2 
rearrangements with junctional analysis. 
Unique, productive VHDHJH-rearrangements isolated and used in pairing assays to test their ability to pair 
with the SL-chain and as a consequence being expressed on the cell surface in a pre-BCR. 
(A,B) µH chains derived from in vitro cultures. (C) µH chains derived from splenic B cells. 
In addition to the classical VH family names (A: VH7183, B: VHJ588) the VH and DH gene element names as 
well as the CDR annotations were assigned using the newer definitions according to IMGT unique naming 
and numbering (8). 
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The sequenced functional and non-functional rearrangements were not clustered within the VH 
gene family locus with regard to the proliferative history of the cells from which the 
rearrangements were obtained (Figure 4). 
In addition to these pre-B cell-derived VHDHJH-rearrangements three functional VHJ558DHJH2 
rearrangements were cloned from splenic B cells. These rearrangements served as positive controls 
in the pairing-assay assuming that these cells, by their origin, must express a µH chain capable of 
forming a pre-B cell receptor. 
3.2.3 Pairing assay: testing the quality of the pre-BCR 
The in vitro pairing assay allowed testing the ability of individual µH chains to pair with the 
surrogate light (SL) chain. Successful pairing of the µH chain with the Vpre-B and λ5 components 
of the SL chain leads to the surface expression of the pre-BCR (2). 
The productively rearranged VH7183DHJH2 or VHJ558DHJH2 rearrangements originating from the 
low, lower-intermediate, higher-intermediate and highly proliferated cell populations and the 
VHJ558DHJH2 rearrangements derived from splenic B cells were used to transduce the Abelson 
virus-transformed, SL chain-expressing, cµ- pre-B cell line 40E1 (9). After expansion of 
transduced cells under selection for puromycin-resistance the cells were tested for cytoplasmic and 
cell surface expression of the µH chain by FACS. Cytoplasmic expression was tested using a 
polyclonal α-Cµ antibody. Testing the surface expression of the pre-BCR was more difficult, due 
to the relatively low density of the pre-BCR on the cell surface. FACS analysis was therefore 
performed by an amplifying staining protocol using monoclonal α-IgMbio in combination with the 
anti-isotype antibody mouse-α-rat IgGbio and streptavidin-PE (see Material and methods). 
Measuring the cytoplasmic expression of µH chain of different clones showed some level of 
variation, which could be at least in part be explained by the random integration of the transgene in 
the transduced cells. Additionally, the puromycin selection allowed many cells to be selected 
without expressing the µH chain (Figure 5A). Therefore in order to quantitate the pairing quality 
(“fitness”) of a pre-BCR the surface µH chain expression was normalized against cytoplasmic µH 
chain expression by determining the mean fluorescence intensities (MFI) for both, surface-positive 
and cytoplasmic-positive µH chain expressing cells. The “fitness” of a pre-BCR was then 
calculated from the ratio of the surface-positive MFI versus the cytoplasmic MFI. 
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Figure 5. Representative FACS profiles of cytoplasmic and surface µH chain expression and pairing 
quality graphs. 
(A) Representative FACS profiles for a weak, intermediate and good pairing. Expression of the µH chains in 
the cytoplasm and detection of cell surface expression of the pre-BCR after transduction in 40E1 cells. 
Indicated gates were used to calculate the mean-fluorescence intensity (MFI) of cytoplasmic and surface µH 
chain-expressing cells. Neg. control: non-productive VHDHJH-rearrangement (dashed line). 
(B, C) Ratio MFI surface+/cytoplasmic+ µH chain expression ordered by the proliferative history of the 
originating cell from low, lower-intermediate, higher-intermediate to highly proliferated. Right column in 
each graph includes the pairing quality of the splenic B cell-derived VHDHJH-rearrangements (pos. control). 
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Although that due to the low density of pre-BCR on the cell surface and the varying cytoplasmic 
expression levels the resolution of this method is not high, the results obtained show that the 
pairing quality can be measured not only as an all-or-nothing event, but at least also semi-
quantitatively. Additionally, this analysis shows a tendency of a better pairing capacity for 
rearrangements derived from cells, which have undergone more cell divisions during the 5 days in 
culture. However, more productive rearrangements would be needed to make a final conclusion 
(Figure 5B). Interestingly, from the only two functional rearrangements derived from the sorted 
subpopulation of low proliferated cells one rearrangement shows a good pairing as compared to the 
splenic B cell-derived rearrangements. The fact that pre B cells have the possibility to rearrange on 
both alleles, if the rearrangement on the first allele failed for a productive rearrangement one could 
assume that this pairing-competent rearrangement originates from the second allele and that 
rearrangement comes to late in time to let the cell substantially proliferate before reaching the next 
stage in differentiation. 
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3.3 Discussion 
According to one hypothesis, well pairing µH-SL complexes (pre-BCR) on the cell surface of large 
pre-B II cells would allow them to undergo more rounds of cell division than if their µH-SL 
complex only loosely pairs, while a non-pairing µH chain abrogates the clonal expansion 
completely, as is demonstrated in SL-chain deficient pre-B cells (4, 5). 
To this end, the present study shows a tendency of a better pairing capacity for VHDHJH-
rearrangements derived from cells, which have undergone more cell divisions. However, many 
more productive µH chain rearrangements would have to be analysed for their pairing capacity in 
order to make a final conclusion. Nevertheless, this study revealed that indeed the capacity of µH-
SLC pairings could be measured not only as an all-or-nothing event, but at least also semi-
quantitatively. 
The main problems of the “pairing-assay” in this study are to deal with the relatively low surface 
expression of pre-BCR and the normalization of these expression levels. The relatively low surface 
expression could be overcome, to some extent, by the use of an amplifying staining procedure 
using an α-IgM and an anti-isotype antibody directed against the first antibody, both biotinylated 
for obtaining a higher number of fluorochrome labeling-positions. For the second problem, 
alternatively, instead of a puromycin selection, which allows many cells to be selected without 
expressing the µH-chain in the cytoplasm, an IRES-driven GFP or other marker proteins could be 
used. GFP would have the advantage to be accessible for direct measurement independently of the 
surface expression of the µH-chain and serve as an internal standard. However, it is known, that 
depending on the integration site, IRES-driven GFP expression does not always correlate with the 
expression level of the first product situated 5’ of the IRES sequence within the mRNA. 
In a recent work, where a somewhat reversed approach was used, the authors received supporting 
results (10). Thus, these authors isolated VHDHJH-rearrangements from early pre-B cells and 
analysed their cytoplasmic and surface expression as pre-BCR in a pre-B cell line. They found, as 
well, that surface expression of the pre-BCR varied between individual clones independently of the 
level of cytoplasmic expression. In addition, they also found a correlation between the pairing 
quality of the analysed rearrangements and the capacity to drive proliferation of pre-B cells by 
introducing the µH chains into pre-B cells of µH-deficient µMT recipient cells and culture them in 
the absence of IL-7. 
Pre-B cells with a non-functional VHDHJH-rearrangement on the first allele, or expressing an SL-
chain non-pairing µH chain can be rescued by rearranging the second allele for an SL (or L)-chain 
pairing µH chain. It could be shown for the few pre-B II cells that productively rearrange both IgH 
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alleles, that only one of the two µH chain proteins actually is capable of pairing with the SL chain 
(2). However, this would lead to a delay in the further differentiation including the proliferative 
expansion. Alternatively these cells are excluded from the proliferative expansion because of that 
delay. The assay, as conducted in this study, might include such cells in the non- or low-
proliferated fractions, although their productive rearrangement is well capable to pair with the SL-
chain (found for 1 clone in the non-low proliferating fraction, which is well capable to pair). This 
process resembles that found in SL-chain deficient strains of mice where the proliferative 
expansion at the large pre-B II stage is abrogated and functional B cell receptors are only expressed 
on the cell surfaces after light-chain gene rearrangements, although the overall output of B cells 
from the bone marrow of such mice is strongly reduced. 
It would be interesting to isolate and analyse the VHDHJH-rearrangements of individual cells sorted 
after 5 days in culture. The prediction would be, that productive VHDHJH rearrangements from a 
secondary rearranged allele and which also show pairing capacity, would be derived from cells, 
which have undergone less proliferation. In this view, the rearrangements on the second allele 
would come too late for the time window during that the proliferative burst occurs. 
 
Still, the outcome in terms of proliferation for an individual pre-B cell in vivo might depend on 
additional factors like the availability of IL-7. It has been demonstrated by others that there is a 
collaborative interaction between the pre-BCR- and the IL-7R-signaling pathway that promotes the 
proliferation of pre-B cells (11). 
Therefore, taken together, an extended model can be proposed, where the quality of the pre-BCR, 
the availability of cytokines (e.g. IL-7) and time determines the amount of proliferation for a given 
B cell. 
PRE-BCR QUALITY  CHAPTER 3   
   
 
74 
3.4 References 
1. Melchers, F., A. Rolink, U. Grawunder, T.H. Winkler, H. Karasuyama, P. Ghia, and J. 
Andersson. 1995. Positive and negative selection events during B lymphopoiesis. Curr 
Opin Immunol 7:214-227. 
2. ten Boekel, E., F. Melchers, and A.G. Rolink. 1998. Precursor B cells showing H chain 
allelic inclusion display allelic exclusion at the level of pre-B cell receptor surface 
expression. Immunity 8:199-207. 
3. Shimizu, T., C. Mundt, S. Licence, F. Melchers, and I.L. Martensson. 2002. 
VpreB1/VpreB2/lambda 5 triple-deficient mice show impaired B cell development but 
functional allelic exclusion of the IgH locus. J Immunol 168:6286-6293. 
4. Rolink, A., A. Kudo, H. Karasuyama, Y. Kikuchi, and F. Melchers. 1991. Long-term 
proliferating early pre B cell lines and clones with the potential to develop to surface Ig-
positive, mitogen reactive B cells in vitro and in vivo. Embo J 10:327-336. 
5. Rolink, A.G., T. Winkler, F. Melchers, and J. Andersson. 2000. Precursor B cell receptor-
dependent B cell proliferation and differentiation does not require the bone marrow or fetal 
liver environment. J Exp Med 191:23-32. 
6. ten Boekel, E., F. Melchers, and A.G. Rolink. 1997. Changes in the V(H) gene repertoire 
of developing precursor B lymphocytes in mouse bone marrow mediated by the pre-B cell 
receptor. Immunity 7:357-368. 
7. Iglesias, A., A. Nichogiannopoulou, G.S. Williams, H. Flaswinkel, and G. Kohler. 1993. 
Early B cell development requires mu signaling. Eur J Immunol 23:2622-2630. 
8. Lefranc, M.P., C. Pommie, M. Ruiz, V. Giudicelli, E. Foulquier, L. Truong, V. Thouvenin-
Contet, and G. Lefranc. 2003. IMGT unique numbering for immunoglobulin and T cell 
receptor variable domains and Ig superfamily V-like domains. Developmental and 
comparative immunology 27:55-77. 
9. Warner, N.L., M.J. Daley, J. Richey, and C. Spellman. 1979. Flow cytometry analysis of 
murine B cell lymphoma differentiation. Immunol Rev 48:197-243. 
10. Kawano, Y., S. Yoshikawa, Y. Minegishi, and H. Karasuyama. 2006. Pre-B cell receptor 
assesses the quality of IgH chains and tunes the pre-B cell repertoire by delivering 
differential signals. J Immunol 177:2242-2249. 
11. Martensson, I.L., and R. Ceredig. 2000. Review article: role of the surrogate light chain 
and the pre-B-cell receptor in mouse B-cell development. Immunology 101:435-441. 
 
 
CHAPTER 4  TSLP IN ADULT LYMPHOPOIESIS 
   
 
 75 
4 TSLP IN ADULT LYMPHOPOIESIS 
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Abstract 
Interleukin 7 (IL-7) plays a crucial role in adult lymphopoiesis, while in fetal life its effect can be 
partially compensated by TSLP. Whether adult hematopoietic progenitor cells are unresponsive to 
TSLP or whether TSLP is less available in adult microenvironments is still a matter of debate. 
Here, we show that increased TSLP availability through transgene (Tg) expression fully restored 
lymphopoiesis in IL-7-deficient mice: it rescued B-cell development, increased thymic and splenic 
cellularities, and restored double-negative (DN) thymocytes, αβ and γδ T-cell generation, and all 
peripheral lymphoid compartments. Analysis of bone marrow chimeras demonstrated that 
hematopoietic progenitor cells from adult wild-type mice efficiently differentiated toward B- and 
T-cell lineages in lethally irradiated IL-7 deficient mice provided TSLP Tg was expressed in these 
mice. In vitro, TSLP promoted the differentiation of uncommitted adult bone marrow progenitors 
toward B and T lineages and the further differentiation of DN1 and DN2 thymocytes. Altogether, 
our results show that adult hematopoietic cells are TSLP responsive and that TSLP can sustain 
long-term adult lymphopoiesis. 
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5.1 Introduction 
The random assembly of V, D and J immunoglobulin (Ig) gene segments in developing 
lymphocytes results in the formation of an immense number of different B cell receptors (BCR) 
able to recognize a diverse repertoire of antigens. However, this random assembly of BCR can lead 
to the formation of Ig receptors that are either autoreactive or functionally impaired. In general, 
such cells are eliminated from the system by negative selection. Receptor editing is an important 
salvage mechanism to eliminate cells bearing potentially autoreactive or signaling-incompetent 
receptors, while at the same time preventing unnecessary deletion of cells. B cells expressing an 
inappropriate BCR can undergo secondary Ig gene rearrangements to form a BCR with a new 
specificity (1, 2). Thus, receptor editing plays a major role in both positive and negative selection 
(3). The main selection checkpoint seems to be at the immature B cell stage, even though a first 
checkpoint occurs already at the pre-BI cell stage. Appropriate signaling by the pre-BCR, which 
consist of µH and surrogate light (SL) chains, is important for the survival of pre-BI cells and their 
developmental progression to cycling large pre-BII cells, whereas insufficient pre-BCR signaling 
results in their developmental arrest.  
Ig light chain (LC) locus rearrangement takes place at the pre-BII cell stage and the first cells 
expressing a complete BCR are newly formed immature B cells. Analyses of production and 
turnover rates revealed severe cell losses among immature B cells, as from the about 20 million 
immature B cells produced in the BM per day, only 20% exited the marrow (4, 5). These findings 
indicate that strong selection takes place at the immature B cell stage. Negative selection may not 
account for all of the losses observed at this point of development, since positive selection in form 
of continuous BCR signaling was shown to be important for survival of both immature and mature 
B cells (6, 7). The mechanism(s) underlying positive selection of B cells are less well characterized 
compared to those for negative selection. One of the main factors for positive selection seems to be 
ligand-independent (tonic) signaling via the BCR. Although several co-receptors and internal 
signaling molecules involved in positive selection have been identified (8), to date it is not clear 
whether B cell survival is directly accomplished by tonic signals, or whether these tonic signals 
lead to the expression and maintenance of survival-promoting intracellular proteins and/or cell 
surface receptors. One candidate for such a receptor is BAFF-R (B cell activating factor belonging 
to the TNF family receptor). For transitional and mature B cell subtypes, it has been shown that 
BAFF-R expression levels are regulated by BCR signaling (9). BAFF signaling via BAFF-R is 
known to be important for the survival of immature B cells as well as their further development 
into mature B cells in the spleen. Both BAFF and BAFF-R deficient mice show a block in B cell 
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differentiation at the transitional type 1 (T1) stage in the spleen, resulting in decreased numbers of 
down-stream transitional type 2 (T2), mature follicular (Fol) and marginal zone (MZ) B cells (10-
12).  
Here we report that during B cell development BAFF-R expression first occurs on a subpopulation 
of CD19+ CD93+ IgM+ CD23- BM B cells and that BAFF-R expression in this subpopulation is 
regulated by signals of a BCR that must not be self-reactive, thus making BAFF-R a useful marker 
for immature B cells that might be positively selected. 
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5.2 Results and Discussion 
5.2.1 BAFF-R is expressed only on IgMhigh immature B cells in the BM 
To characterize our newly generated monoclonal antibodies against mouse BAFF-R (13) we used 
five-color flow cytometric analyses with antibodies against CD19, CD21, CD23, CD93 and 
mBAFF-R (clones 7A5 and 9B9, respectively). As shown in figure 1A, anti-mBAFF-R clone 9B9 
detects BAFF-R on splenic T1 (CD19+ CD93+ CD21- CD23-), T2/3 (CD19+ CD93+ CD21+ CD23+), 
follicular (CD19+ CD93- CD21+ CD23+) and marginal zone B cells (CD19+ CD93- CD21+ CD23-). 
On all splenic B cell subsets, BAFF-R was expressed homogenously and to the same extent. 
BAFF-R expression could also be detected on both B-1a (CD19+ CD5+) and B-1b (CD19+ CD11b+) 
B cells from the peritoneal cavity. In contrast, no expression of BAFF-R could be detected on 
CD4+ or CD8+ splenic T cells. Similar results were obtained using another anti-mBAFF-R antibody 
(clone 7A5, data not shown).  
Contrary to the splenic and peritoneal B cells, BAFF-R expression on BM B cells was 
heterogeneous. We found that there was no FACS-detectable expression of BAFF-R on B220+ 
IgM- B cells (Figure 1B, gate A), but that BAFF-R was highly expressed on B220high IgM+ 
recirculating B cells (Figure 1B, gate C). Interestingly, by gating on B220int IgM+ newly formed B 
cells we observed that this was a mixed population with regard to BAFF-R expression (Figure 1B, 
gate B). A BAFF-R positive fraction could be clearly distinguished from a BAFF-R negative 
fraction, with about 40% of the newly formed B cells being positive for BAFF-R in a 6-8 week old 
C57BL/6 mouse. BM B cells defined as B220int IgM+ are the progeny of pre-BII cells and express 
for the first time a complete BCR. Thus, B cells in this compartment are in a developmental stage 
where BCR editing may occur. This prompted us to look for a correlation between BAFF-R 
expression and putative BCR editing. 
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Figure 1. BAFF-R expression on B and T cell subsets. 
(A) Splenic B cell subsets (upper panel) were delineated using markers CD19, CD93, CD21 and CD23 and 
BAFF-R expression on transitional T1 and T2/3 B cells as well as mature MZ and Fol B cells was analyzed. 
Furthermore, BAFF-R expression was measured on B-1a (CD19+ CD5+) and B-1b (CD19+ CD11b+) B cells 
from the peritoneal cavity as well as on splenic CD4+ and CD8+ T cells. Dotted line histograms represent the 
negative controls. (B) Bone marrow B cell subsets were delineated using markers B220 and IgM, and BAFF-
R expression on IgM- B220+ cells (A), IgM+ B220low newly formed B cells (B) and IgM+ B220high 
recirculating B cells (C) was analyzed. Dotted line histograms represent the negative controls. 
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5.2.2 BAFF-R expression levels correlate with surface IgM levels 
BCR editing is known to be associated with low levels of surface IgM expression on B cells in the 
BM (14). If our assumption was correct, that there was a correlation between BAFF-R expression 
and BCR editing, there should also be a correlation between BAFF-R and IgM expression. More 
recently published data revealed that B cell maturation to mature, long-lived B cells occurs not 
only in the spleen but might be also occurring in the BM (15, 16). To rule out that our B220int IgM+ 
newly formed B cell subpopulation contained more mature BM specific B cell developmental inter-
mediates, we used the surface markers CD19, CD93, IgM and CD23 to delineate differentiation 
stages (Figure 2A). We found that CD19+ CD93+ IgM+ CD23+ BM B cells were all positive for 
BAFF-R, with an expression level similar to splenic B cells (Figure 2B, right), whereas CD19+ 
CD93+ IgM+ CD23- BM B cells are heterogeneous concerning BAFF-R expression (Figure 2B, 
left). Since it could only be assumed that within the CD19+ CD93+ IgM+ CD23- B cells there is a 
BAFF-R- and a BAFF-R+ fraction, we sorted and reanalyzed the putative two populations. We 
found, that two clearly definable fractions exist, a BAFF-R- and a BAFF-R+ one (Figure 2C, left). 
Upon analysis of the surface IgM expression we found that the level was lower on the BAFF-R- 
fraction of CD19+ CD93+ IgM+ CD23- B cells compared to the BAFF-R+ fraction (Figure 2C, 
right). Since cells showing low levels of IgM expression in BM have been indicated to undergo 
receptor editing (14), our findings might suggest that BAFF-R expression discriminates between 
receptor editing and non-editing immature B cells. 
5.2.3 Analysis of BCR knock-in mice 
Further evidence supporting our hypothesis comes from the analysis of BCR knock-in B1-8Hi; 3-
83κi mice which carry pre-rearranged HC and LC genes in their appropriate genomic context and 
express only an innocuous BCR consisting of the B1-8 HC and the 3-83 κ-LC. As B cell receptor 
editing is the main mechanism through which B cells expressing autoreactive BCRs are eliminated, 
these mice do not have B cells that undergo receptor editing. Staining of BM B cells of B1-8Hi; 3-
83κi mice for B220 and IgM revealed that there are almost no B220+ IgM- progenitor B cells (17). 
This observation has been explained by the direct and rapid maturation of progenitors into 
immature B cells due to the absence of negative selection and receptor editing. Our finding, that 
BAFF-R is expressed only on newly formed B cells that need not to be eliminated by negative 
selection, leads to the assumption that all of the newly formed immature B cells in the BM
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Figure 2. Newly formed B cells from the 
bone marrow can be subdivided into a 
BAFF-R- and a BAFF-R+ fraction. 
(A) BM B cell subsets were delineated 
using markers CD19, CD93, CD23 and 
IgM. (B) BAFF-R expression on newly 
formed CD19+ CD93+ IgM+ CD23- B cells 
(left) and on mature CD19+ CD93+ IgM+ 
CD23+ B cells (right). Thin line histograms 
represent the negative controls. (C) Newly 
formed CD19+ CD93+ IgM+ CD23- B cells 
(B, left picture) where sorted according to 
BAFF-R expression and reanalyzed. The 
left overlay represents the reanalysis of the 
sorted BAFF-R- fraction (thin line 
histogram) and BAFF-R+ fraction (thick 
line histogram). The right hand overlay 
shows the IgM expression on IgM+ CD23- 
BAFF-R- (thin line histogram) and BAFF-
R+ (thick line histogram) cells. 
of these knock-in mice should homogenously express BAFF-R. FACS staining of the BM of the 
B1-8Hi; 3-83κi mice for IgM, B220 and mBAFF-R revealed that, in fact, the newly formed IgMhigh 
B220int B cells express BAFF-R homogenously (Figure 3, fraction B), which is in contrast to the 
finding in BM of WT mice (Figure 1B, fraction B). As expected and in accordance with the results 
obtained for WT mice (Figure 1B, fractions A and C), IgM- B220+ B cells in these knock-in mice 
are negative for BAFF-R expression (Figure 3, fraction A), and all IgM+ B220high recirculating B 
cells express BAFF-R (Figure 3, fraction C). This result supports our assumption, that BAFF-R is 
expressed first on immature BM B cells that have passed the negative selection process. 
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Figure 3. BAFF-R is expressed homogenously on newly formed BM B, which do not undergo receptor 
editing. 
Bone marrow B cell subsets from A) WT and B) B1-8 transgenic knock-in mice were delineated using 
markers B220 and IgM, and BAFF-R expression on IgM- B220+ cells (A), IgM+ B220low newly formed B 
cells (B) and IgM+ B220high recirculating B cells (C) was analyzed. 
5.2.4 BAFF-R expression correlates negatively with RAG-2 expression and 
BCR editing 
B cells that undergo receptor editing need to express RAG-1 and RAG-2, as these proteins are 
absolutely necessary for V(D)J recombination. Considering that BAFF-R expression might be 
related to BCR editing, there might also be a correlation with RAG expression. Therefore, we 
analyzed BCR LC editing and RAG-2 expression in B cell populations subjected to different in 
vitro conditions. Thus, we sorted κ-LC+ CD19+ CD93+ CD23- BAFF-R- (referred to as CD23- 
BAFF-R-), κ-LC+ CD19+ CD93+ CD23- BAFF-R+ (referred to as CD23- BAFF-R+) and κ-LC+ 
CD19+ CD93+ CD23+ BAFF-R+ (referred to as CD23+ BAFF-R+) B cells from the BM and 
incubated them either in the presence or absence of an anti-κ-LC antibody. After 36 h we analyzed 
the cells by FACS, using an anti-λ-LC antibody to follow LC editing from κ to λ. RAG-2 
expression was determined by semi-quantitative RT-PCR. When cultured in the absence of
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Figure 4. RAG-2 is expressed only in BAFF-R- newly formed B cells from the BM, but can be induced 
in BAFF-R+ newly formed B cells from the BM by culturing with anti-κ-LC antibody. 
(A, B) B cells from the BM were sorted as CD19+ CD93+ κ-LC+ CD23- BAFF-R- (left panel), CD19+ CD93+ 
κ-LC+ CD23- BAFF-R+ (middle) and CD19+ CD93+ κ-LC+ CD23+ BAFF-R+ (right panel) and incubated for 
36 h in medium alone (A) or in the presence of 25 µg/ml anti-κ-LC antibody (B). LC editing from κ- to λ-LC 
was analyzed using IgM and λ1+2-LC specific antibodies. (C) RAG-2 expression was measured by semi-
quantitative PCR for BM B cell subpopulations sorted and cultured as mentioned in A and B. 
anti-κ-LC antibody, CD23- BAFF-R- B cells (Figure 4A, left) underwent extensive LC editing, as 
was apparent by 7.2% of previously κ-LC+ cells that had become λ-LC+. About 15 % of the cells 
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had down-regulated their BCR and were now IgM negative. These cells were probably not able to 
further edit their LCs and presumably were in the process of apoptosis. Interestingly, both of the 
other B cell subtypes analyzed, which were both BAFF-R+, did not show any sign of receptor 
editing and kept expressing κ-LC BCRs (Figure 4A, middle and right). RT-PCR analysis revealed, 
that only the BAFF-R- subpopulation expressed RAG-2, whereas both of the BAFF-R+ 
subpopulations were negative for RAG-2 expression (Figure 4C, upper panel). 
This result supports the previous finding and confirms, that only CD23- BAFF-R- BM B cells can 
undergo V(D)J recombination and LC editing, whereas CD23- BAFF-R+ as well as CD23+ BAFF-
R+ BM B cells did not undergo LC editing, probably because they expressed already a harmless 
(non-autoreactive) and functional BCR. 
When we performed the same experiment in the presence of an anti-κ-LC antibody in order to 
induce receptor editing (Figure 4B), then CD23- BAFF-R- BM B cells showed increased LC 
editing, which was apparent from the about 17% λ-LC+ B cells (Figure 4B, left). As before, the two 
BAFF-R+ subpopulations analyzed behaved almost the same, showing around 6% λ-LC+ cells in 
the case of CD23- BAFF-R+ cells and 2% λ-LC+ cells for CD23+ BAFF-R+ cells (Figure 4B, 
middle and right). Cells that were not able to edit the BCR from κ- to λ-LC showed reduced 
surface IgM expression levels (Figure 4B). In the presence of the anti-κ-LC antibody, RAG-2 
expression could be detected for all three subpopulations, but BAFF-R+ cells showed lower levels 
than BAFF-R- cells (Figure 4C, lower panel). 
These results clearly indicate that CD23- BAFF-R- immature B cells do not yet express an 
appropriate BCR, as evidenced by the still existing RAG-2 expression and the high percentage of 
cells undergoing LC editing. Moreover, our findings indicate that BAFF-R expression does not 
inhibit LC editing, since BCR ligation of both CD23- BAFF-R+ and CD23+ BAFF-R+ B cells was 
able to re-induce RAG expression and LC editing. In this context it is worthwhile noting that LC 
editing in CD23- BAFF-R+ and CD23+ BAFF-R+ B cells by the anti-κ-LC antibody could not be 
prevented by the addition of BAFF (data not shown). These findings suggest, that the B cell 
autoimmunity observed in transgenic mice, which over-express BAFF (18, 19) is not due to BAFF 
interfering with negative selection and/or receptor editing of autoreactive immature bone marrow B 
cells, but rather might be a result of BAFF rescuing anergic/self-reactive B cells in the periphery 
(20). 
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5.2.5 Changes of surface BAFF-R expression levels upon BCR ligation 
depends on the B cell maturation stage  
To test whether BAFF-R expression levels change upon BCR ligation, IgM+ CD93+ BAFF-R- 
CD23- and IgM+ CD93+ BAFF-R+ CD23- as well as IgM+ CD93+ BAFF-R+ CD23+ B cells from the 
BM, and transitional T1 and T2/3 and mature follicular B cells from the spleen were purified by 
cell sorting. Cells were then incubated either in the presence or absence of anti-IgM antibody. 
FACS analysis after 36 h revealed, that all BM B cell subsets analyzed expressed BAFF-R at the 
same level when cultured in the absence of anti-Ig antibody (Figure 5A, thick solid histogram).  
 
 
Figure 5. Surface BAFF-R levels on B cell subsets change during culturing with anti-IgM. 
(A) BM B cells were sorted as CD19+ CD93+ κ-LC+ CD23- BAFF-R- (left panel), CD19+ CD93+ κ-LC+ 
CD23- BAFF-R+ (middle) and CD19+ CD93+ κ-LC+ CD23+ BAFF-R+ (right panel) and expression levels of 
BAFF-R were analyzed after culturing the cells in the absence (thick line histograms) or presence (dotted line 
histograms) of anti-IgM antibody for 36 h. Thin line histograms represent the negative controls. (B) Splenic 
B cells were sorted as CD19+ CD93+ CD23- κ-LC+ (T1), CD19+ CD93+ CD23+ κ-LC+ (T2/3) or CD19+ 
CD93- CD23+ κ-LC+ (Fol B) and BAFF-R expression was analyzed after culturing the cells in the absence 
(thick line histograms) or presence (dotted line histograms) of anti-IgM antibody for 36 h. Thin line 
histograms represent the negative controls. 
 
BAFF-R EXPRESSION AND B CELL RECEPTOR EDITING CHAPTER 5 
   
 
 
96 
IgM+ CD93+ CD23- BAFF-R- B cells become BAFF-R+, since they continued their developmental 
program. When incubated in the presence of the anti-IgM antibody, we observed that BAFF-R was 
down modulated in all BM B cell subtypes analyzed (Figure 5A, dotted histogram). Incubation of 
CD23- BAFF-R- cells in the presence of antibody (Figure 4B, left) leads to down-modulation of 
IgM expression in more than 80% of the cells. This population also shows low to negative 
expression of BAFF-R. The splenic transitional T1 and T2/3 subpopulations behaved the same as 
the BM subpopulations, as they kept BAFF-R expression in the absence of anti-IgM antibody and 
down-regulated BAFF-R in the presence of the antibody (Figure 5B, left and middle). 
Interestingly, Fol B cells also kept BAFF-R expression when cultured in the absence of the 
anti-IgM antibody, but in contrast to BM and splenic transitional type B cells, they up-
regulated BAFF-R expression in the presence of BCR ligation (Figure 5B, right). Thus, our results 
suggest that BAFF-R expression is regulated by BCR signaling and that the outcome of BCR 
signaling on BAFF-R expression is B cell developmental stage dependent i.e. down-modulation on 
immature B cells and up-regulation on mature B cells. 
Findings in support of this assumption come from the observations made in mice lacking both Rac-
1 and Rac-2. Such mice show defective BCR signaling, resulting in diminished numbers of splenic 
B cells, but normal numbers of BM B cells. Furthermore, this impaired BCR signaling also leads to 
reduced levels of BAFF-R, pointing to a direct regulation of BAFF-R expression by BCR signaling 
via the Rac-1 and Rac-2 pathway (21).  
Our finding that in B cells susceptible to negative selection, engagement of the BCR leads to down-
regulation of BAFF-R expression might suggest that their survival time upon BCR ligation is 
reduced and therefore these cells might be more easily eliminated. This could be part of the 
mechanisms by which autoreactive B cells are deleted. On the other hand, however, absence of 
down-modulation of the BAFF-R upon BCR engagement by immature B cells might lead to 
autoimmunity. 
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6 NEWB CELLS, A PUTATIVE NEW B CELL 
POPULATION 
6.1 Introduction 
Immature sIgM+ B cells produced in the bone marrow migrate to the spleen, through the terminal 
branches of the splenic central arterioles, where they further differentiate into mature, immuno-
competent B cells. In adult mice 2x107 immature B cells are produced daily of which 10-20% enter 
the spleen, but only 5-10% will enter the pool of mature B cells. Several distinct immature and 
mature B cell compartments have been characterized by their properties such as marker expression, 
functionality, turnover and life span. However, some of the defined compartments might yet still 
represent heterogeneous cell populations. The development of monoclonal antibodies (clones 493 
and AA4.1) against the complement C1q-like receptor C1qRp (CD93) facilitated the analysis of 
immature (CD93+) and mature (CD93-) B cell compartments (1, 2). 
The mature B cells in the spleen of a non-immunized mouse are represented predominantly by the 
relatively long-lived, circulating follicular B cells (FOB: CD19+ CD93- CD21+ CD23+ IgM+ IgDhi) 
and to a lesser extent by the more sessile marginal zone B cells (MZB: CD19+ CD93- CD21hi 
CD23-/lo IgMhi IgDlo), which are exclusively located in the marginal zone of the spleen. 
However, it is not clear yet what determines the selection of B cells into one or the other known 
mature B cell compartment. Factors, which have suggested involve the specificity of the B cell 
receptor, BCR-mediated signaling strength, B cell homeostasis, ontogeny and origin of precursors 
(3-5). Precursors of the FOB and the MZB cells are not well defined, as well as where in the FOB 
and MZB development their paths branch off (see General Introduction). 
The mature B cell compartment (CD19+ CD93-) can be subdivided into CD23+ cells comprising 
mainly the FOB cells and into CD23-/lo cells. 
By looking on the second compartment, it became apparent that this population is heterogeneous 
(Figure 1). Within this population, which includes the CD21hi expressing MZB cells, a reasonable 
fraction of cells, however, expresses low levels of CD21. Compared to the MZB cells, which are 
relatively large in size and express high levels of IgM, but low levels of IgD, the cells of this 
fraction are also smaller in size and express intermediate levels of IgM and IgD (6). One could, 
therefore, speculate that this new B-cell subset represents yet another B-cell subpopulation. 
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Figure 1. Putative new B cell population in spleen. 
Splenocytes (C57BL/6) were stained for CD19, CD93, CD21 and CD23. Gating for CD19+ CD93- cells 
reveals a CD21hi population comprising MZB cells and a CD21-/lo population, which is smaller in size (FSC) 
as the CD21hi cells. 
In this study it is attempted to characterize this new B-cell subset and try to verify that it is a truly 
new, so far not defined, B-cell subpopulation. To that end, the cells were tested for a panel of 
additional markers and were also further characterized in various functional assays. The results 
obtained are discussed in the context of the well-described splenic immature and mature B cell 
compartments. 
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6.2 Results 
6.2.1 Discovery of a putative new B cell population within the mature B cell 
compartment 
When mature splenic B cells (CD19+ CD93-) are stained additionally for CD21 (complement 
receptor for C3d fragment) and CD23 (low affinity Ig-E receptor) surface markers, two major 
populations become visible (Figure 2). The majority (>80%) is CD23hi and comprises the FOB 
cells, whereas a minority (<10%) is CD21hi and comprises the MZB cells. The remaining, 1-4% 
double negative cells are the subject of this study. This putative new B cell population (CD19+ 
CD93- CD21-/lo CD23-/lo) was tested for the expression of a panel of other markers, which are 
differentially expressed in the characterized immature and mature B cell compartments of the 
spleen.  
 
Figure 2. Putative new B cell population (CD19+ CD93- CD21-/lo CD23-/lo) in the spleen of a C57BL/6 
mouse. 
Splenocytes (C57BL/6) were stained for CD19, CD93, CD21 and CD23. Gating for CD19+ CD93- cells 
reveals FOB (CD21+ CD23hi), MZB (CD21hi CD23-/lo) cells and the putative new B cell population (CD21-/lo 
CD23-/lo). 
B1-a cells have been described as being CD21- CD23-. Therefore these cells might fall into our 
newB cell gate. However, compared to the B2 B cells, B1-a cells are in addition CD5+ (7). 
Indeed, staining for CD5 revealed two subpopulations within this cell population. A subpopulation 
was CD5-, while a second subpopulation was clearly CD5+. The CD5- cells are smaller in size 
(forward scatter) than the CD5+ cells and make up around 60% of the total CD19+ CD93- CD21-/lo 
CD23-/lo cell population in the spleen of wild-type C57BL/6 mice (Table 2). This putative new B 
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cell population was named “newB” and defined as CD19+ CD93- CD21-/lo CD23-/lo CD5- cells 
(Figure 3). 
The CD5+ subpopulation (40%) most probably comprises the B-1 cell population B-1a (7). 
Compared to the CD5- newB cells as well as the FOB and MZB cells, the CD5+ subpopulation 
showed a dull staining for the B220 marker (data not shown). 
 
Figure 3. New B cells are CD5-. 
Mature B cell populations of non-immunized 8-wks-old C57BL/6 mice. Representative FACS profiles (n=5). 
6.2.2 Surface markers expressed on newB cells compared to the FOB and 
MZB cell compartment 
Two different approaches were used to further characterize the newB cell compartment 
phenotypically. Either the newB cells (CD19+ CD93- CD21-/lo CD23-/lo CD5-) were sorted in a 5-
colour FACS sort and the sorted population re-stained for additional surface markers or splenocytes 
were depleted of CD5+ cells, immature CD93+ B cells as well as NK1.1+ cells (C57BL/6 
background only) using magnetic-bead separation (MACS). Then the MACS-purified mature B 
cells were stained for B220, CD21 and CD23 in combination with antibodies against additional 
surface markers. For comparison FOB and MZB cells were included in the analysis. The results are 
shown in figure 4 and are summarized in table 1. 
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Figure 4. Surface marker expression on newB cells compared to FOB and MZB cells. 
Splenocytes from C57BL/6 mice were depleted for CD93+, CD5+ and NK1.1+ cells by MACS and stained 
with B220, CD21, CD23 and one of the indicated markers for FACS analysis. FOB (black: B220+ CD21+ 
CD23hi); MZB (grey: B220+ CD21hi CD23-/lo); newB (red: B220+ CD21-/lo CD23-/lo); negative control (grey 
dashed line). Markers used were for (A) B cell and maturation; (B) Homing and adhesion; (C) Activation 
markers. 
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Thus, both IgM and IgD isotypes are differentially expressed on FOB and MZB cells. The newB 
cells demonstrate a level of IgM expression, which is as high as for MZB cells, but some cells 
show a lower IgM expression level. It cannot completely ruled out at that stage, that this low IgM-
expressing cells yet represent another population or might even be in transit from or to the newB 
cell compartment. The IgD expression level is as low and varied like that seen in MZB cells. 
Compared to them, FOB cells express IgD more homogenously and at higher levels. 
Both, CD19 and B220 are expressed at slightly lower levels on newB cells than on FOB and MZB 
cells. CD19 functions to mediate the amplification of Src family protein kinase activity in BCR 
signaling, and therefore its level is critical for B cell activation. Mice over-expressing CD19 on 
their B cells spontaneously develop autoimmunity (8). 
The transitional 1 (T1) B cells are IgDlow CD21- CD23- CD93+ and express high levels of CD24 
(9). In our FACS analysis newB cells show a higher expression level than MZB and FOB cells, 
suggesting that the newB cells might be of a less mature phenotype, although, by definition they 
belong to the mature B cell compartment, as they are CD93-. 
BAFF signaling through BAFF-R is known to be important for the survival of immature B cells 
and their further development into mature B cells. BAFF-R levels are regulated by BCR signaling 
and absence of BAFF-R largely prevents the development of B-2 B cells beyond the T1 stage (10, 
11). Testing B cells for BAFF-R expression using two different anti-BAFF-R antibodies recently 
developed in our group (12) showed that newB cells do express BAFF-R, although slightly less 
than FOB and MZB cells. However, we could show that expression of BAFF-R can be detected as 
early as on a population of CD19+ CD93+ CD23- bone marrow cells (Rauch et. al., for submission). 
Within the mature B cell compartment CD9 has been so far described as a unique marker for MZB 
cells, subsets of B-1 cells and plasma cells (13). While the MZB cells are CD9+, both the newB and 
the FOB cells do not express CD9. 
In contrast to B-1 cells, which are defined in part through their CD11b+ phenotype (14), both newB 
and FOB cells are negative for CD11b, while MZB cells show a low expression. 
NewB, FOB and MZB do express CD44 to the same extent. CD44 functions as a receptor for 
extracellular matrix components including hyaluronic acid, is implicated in lymphocyte homing 
and is elevated on activated B cells (15). 
L-selectin CD62L mediates lymphocyte homing to high endothelial venules of peripheral lymphoid 
tissue and to activated endothelium at inflammatory sites (16). Interestingly, FOB cells express 
CD62L, while both MZB and the newB cells are CD62L-. It is worth the notion that FOB cells, in 
contrast to the sessile MZB cells, are re-circulating cells. This may indicate that newB cells 
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represent a sessile B cell population much as MZB cells, alternatively, they do not fulfill other 
criteria to leave for the circulation.  
Surface marker expression on newB cells in comparison to 
FOB and MZB cells 
(A) B cell and B cell maturation 
 newB FOB MZB 
CD19 + + + 
IgM ++ + ++ 
IgD + ++ + 
CD21 -/+ + -/+ 
CD23 -/+ + -/+ 
CD24 ++ + + 
CD93 - - - 
BAFF-R + + + 
(B) Homing, adhesion 
 newB FOB MZB 
CD9 - - + 
CD11b (Mac-I) - - -/+ 
CD44 + + + 
CD62L - + - 
(C) Activation 
 newB FOB MZB 
CD25 - - - 
CD80 - - - 
CD86 - - - 
CD180 (RP105) + + ++ 
MD-1 + + ++ 
Table 1. Overview: surface marker expression on newB cells compared to FOB and MZB cells. 
(A) B cell and B cell maturation; (B) Homing and adhesion; (C) Activation markers. 
Tested surface markers known to be elevated on activated B cells, CD25, CD80 and CD86 are not 
higher expressed on newB cells as compared to the naive FOB or MZB cells, suggesting again, that 
newB cells are not in an activated state. Additionally, it was shown that memory B cell populations 
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have increased levels of CD80 and CD86 expression, which again, makes it unlikely that newB 
cells are related to memory B cells (17, 18). 
The TLR proteins CD180 (RP105) and MD-1, known to influence signaling via the BCR in context 
of bacterial antigens such as LPS, are expressed at a lower level than in FOB, and especially lower 
than in MZB cells. The higher expression level of these proteins in MZB cells has been also 
described by others and may help these cells to more readily respond to bacterial antigens (19-21). 
 
6.2.3 NewB cells can be found in lymph nodes 
The major mature B cell population in lymph nodes is represented by the recirculating FOB cells. 
In contrast, MZB cells are absent in lymph nodes as they exclusively reside in the spleen. To 
investigate whether newB cells are present in lymph nodes, we performed 5-colour FACS analyses 
of cells isolated from axillary, inguinal and mesenteric lymph nodes. 
Indeed, newB cells could be detected, although to relatively smaller numbers compared to the 
spleen (Figure 5 and Table 2). The CD5+ cells could also be found in low numbers, which is not 
surprising, since B-1a cells have been described to be found in lymph nodes, as well (22, 23). 
Interestingly, the ratio between newB and CD5+ B cells is similar in the spleen as in the lymph 
nodes (Table 5). 
 
Figure 4. NewB cells can be found in low numbers in LNs. 
Mature B cell populations of non-immunized 8-wks-old C57BL/6 mouse. (LNs: pooled axillary, inguinal and 
mesenteric). Representative FACS profiles (n=5). 
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NewB cell population size within the mature B cell compartment in spleen and 
lymph nodes (% of total mature B cell compartment) 
Population Spleen Lymph nodes 
FOB 84.2 ± 1.0 % 92.8 ± 1.1 % 
MZB 6.2 ± 0.6 % — 
newB 2.1 ± 0.1 % 0.9 ± 0.3 % 
CD5+ B 1.4 ± 0.2 % 0.6 ± 0.2 % 
% of newB cells within the CD19+ CD93- CD21-/lo CD23-/lo population 
newB 60.2 ± 2.7 % 66.1 ± 3.7 % 
CD5+ B 39.8 ± 2.7 % 33.9 ± 3.7 % 
Table 2. NewB cell population size within the mature B cell compartment in spleen and lymph nodes. 
Cell suspensions from spleen and lymph nodes (pooled axillary, inguinal and mesenteric) of non-immunized 
8-wks-old C57BL/6 mice (n=5) were stained with antibodies against CD19, CD93, CD21, CD23 and CD5 
and analysed by 5-colour FACS. 
6.2.4 Do newB cells have somatically hypermutated Ig chains? 
Somatic hypermutation is an important aspect in generating antibody diversity in the maturation of 
an immune response. The process leads to higher affinity antibodies with the final goal to elicit a 
better response. 
The λ locus is the smallest of the mouse Ig loci, and germline sequence differences combined with 
junctional imprecision in joining Vλ-Jλ gene elements give only little diversity. Therefore the λ 
locus is a convenient target for the analysis of somatic hypermutations (24). 
The analysis of the λ1 light chains in newB cells should give information if this putative new B cell 
population is involved in germinal center reactions and might be related to some form of memory 
B cells. It could be shown for germinal center B cells (B220+ PNAhi) that they contain readily 
hypermutated Vλ1-Jλ1 rearranged genes (25). 
For the λ1 light chain analysis newB (CD19+ CD93- CD21-/lo CD23-/lo), FOB (CD19+ CD93- CD21+ 
CD+) and immature transitional T1 (CD19+ CD93- CD21- CD23-) B cells were sorted from 
splenocytes of C57BL/6 mice. λ1 light chain-rearrangements were amplified from genomic DNA 
of sorted cells by a semi-nested PCR (26). The resulting PCR products were cloned generating λ1 
light chain-libraries. Sequences obtained from each library were aligned and analysed for mutations 
in the CDR regions (27). 
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We found only two mutations in the set of analysed unique λ1 light chain rearrangements in FOB 
cells, which are most probably due to PCR errors and none in the analysed newB and MZB cells 
(Table 3). 
Thus no somatic hypermutations were detected in the set of λ1 light chains analysed in newB, FOB 
and transitional T1 cells. For germinal center B cells (B220+ PNAhi) it has been reported that 77% 
of all analysed clones showed >1 mutation per sequence, irrespective whether the Vλ1-Jλ1 junction 
was in- or out-of-frame (25). Thus, our finding is significant and demonstrates that the newB cells 
are not subjected to somatic hypermutation and most probably do not belong to germinal center B 
cells. 
6.2.5 Response of newB cells to B cell stimuli 
NewB cells were tested for their ability to respond to mitogenic stimulation with LPS and the 
oligodeoxynucleotid CpG, or to a BCR-dependent stimulus (α-IgM) in combination with BCR-
independent stimuli (α-CD40 or IL-4) mimicking T cell-derived signals. The responses were 
compared with those of immature, transitional B cells and of mature B cell populations. 
To get sufficient numbers of the rare newB cells a purification protocol was established where 
splenocytes were first depleted of NK1.1+, CD93+ and CD5+ cells by magnetic bead separation 
(MACS). The remaining splenocytes were stained for B220, CD21 and CD23 expression. From 
this population, enriched for CD93- B cells, a preparation of newB cells (B220+ CD21-/lo CD23-/lo) 
could then be FACS-sorted in numbers sufficient for B cell stimulation assays (1x105 cells/well in 
a 96-well plate). The immature, transitional B, FOB and MZB cells were directly FACS-sorted by 
a 4-colour staining (CD19, CD93, CD21 and CD23). 
Purified newB, transitional B and mature B cells were cultured in vitro in the presence of LPS, α-
IgM + α-CD40 or α-IgM + IL-4 for 3 days. The cellular proliferation was quantified by the 
incorporation of [3H]thymidine. 
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Figure 6. NewB cells proliferate in response to LPS and to α-IgM + α-CD40 to a lesser extent. 
FACS-sorted immature and mature B cells, (A) newB, FOB and MZB cells, (B) newB, FOB, MZB, 
transitional B cells (T1 and T2/3), were stimulated in vitro with LPS [10 µg/ml], α-IgM [25 µg/ml] + α-
CD40 [20 µg/ml] or α-IgM [25 µg/ml] + IL-4 [10% IL-4 sup.]. (C) NewB, FOB and MZB cells were 
stimulated in vitro with the oligodeoxynucleotid CpG (CpG1826 [0.5 µg/ml]). Cells were incubated for 72h. 
The last 9 hours dividing cells were labeled by adding [3H]thymidine (1µCi/96-well). Control: unstimulated 
cells. 
NewB cells did respond to LPS and to α-IgM + α-CD40, although they proliferated to a lesser 
extent than the mature FOB and MZB cells. However, a significant response to α-IgM + IL-4 could 
not be detected. Interestingly, the immature transitional T2/3 cells responded to all stimuli 
significantly higher than the newB cells (Figure 6A and B). 
Motifs containing unmethylated CpG dinucleotides in bacterial DNA or in synthetic 
oligodeoxynucleotides (ODN) are known to activate B cells and promote their proliferation via 
TLR9 signalling (28, 29). NewB cells treated with CpG responded well, comparable to FOB cells 
(Figure 6C). 
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6.2.6 NewB cells in different mouse strains 
Furthermore, the existence and numbers of newB cells in different strains were analysed. The 
analysed strains were either impaired in the output of immature B cells from the bone marrow (λ5 
deficient) or in the formation of germinal center and memory B cells (CD40-deficient), or have an 
enlarged mature B cell compartment due to transgenes for survival factors (e.g. Bcl-2 or BAFF 
transgenic mice)(Figure 7). 
 
Figure 7. NewB cells compared to other B cell populations in the spleen of wild-type, different k.o. and 
transgenic mouse strains. 
Splenocytes from C57BL/6, CD40-/-, λ5-/-, hBAFF tg (BALB/c) and Bcl-2 tg mice (n=2-4) were analysed for 
CD19, CD93, CD21, CD23 and CD5 by 5-colour FACS analysis. 
NewB cells could be detected in spleens of λ5- and CD40-deficient, as well as in Bcl-2 and hBAFF 
transgenic mouse strains.  
Absolute numbers of newB cells were reduced in λ5-deficient mice and must reflect the lower 
influx to the spleen of immature B cells from the bone marrow as there is an overall reduction of 
CD19+ cells in these mice. However, the proportion of newB cells as compared to the total CD19+ 
cells is similar as in wild-type C57BL/6 mice (~2%). 
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NewB cells in the mouse lacking CD40, which show impaired Ig class switching and lack germinal 
center formation (30) were found slightly reduced in absolute numbers and their proportion to total 
CD19+ cells was less than in wild type mice. 
In Bcl-2 tg mice the absolute number of newB cells is increased, as are all other B cell populations 
analysed. However, the proportion of the newB cells as compared to the total CD19+ cells remains 
similar to the number found in wild-type C57BL/6 mice.  
Interestingly, in hBAFF tg mice, where the number of FOB, MZB and CD5+ B cells, and especially 
the proportion of MZB cells is increased, the total number of newB cells remains similar to what 
was found in wild-type C57BL/6 mice, while the proportion of newB cells as compared to the total 
CD19+ cells is reduced. 
6.2.7 Turnover of newB cells compared to other immature and mature B 
cell populations in the spleen 
Finally, the turnover of newB cells was assed and compared to other immature and mature splenic 
B cells. 4-5 weeks old C57BL/6 mice were injected i.p. with the thymidine analogue BrdU and 
thereafter treated with BrdU in the drinking water for 18 days. The incorporation of BrdU into the 
DNA of splenic B cell populations was determined at the end of the BrdU-labeling period and after 
a chase period of 21 days (n=5 per group). Cells were isolated by FACS-sort with phenotypic 
markers (see above) to distinguish the newB cells, transitional T1 and T2/3, FOB, MZB and CD5+ 
B cells. After the isolation BrdU+ cells in each sorted population were detected with an intracellular 
anti-BrdU staining by FACS (Figure 8). 
Transitional B cells showed an almost complete BrdU labeling after 18 days, being somewhat 
lower (88%) for the T2/3 cells, but in accordance with their sequential development. The nearly 
complete disappearance after the chase period indicates a high turnover of these cells and reflects 
the transitional state of these cells in development. 
FOB and MZB cells were labeled to 40% and 58%, respectively after 18 days. Compared to the 
transitional B cells, these major mature splenic B cell populations remained to 27% and 45%, 
respectively, BrdU+ after the chase period. This data is indicative of a slow turnover and most 
likely reflects the stage and function of these cells as being differentiated to relatively long-lived B 
cells and fulfill the function to monitor the organism for antigen. 
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Figure 8. Turnover of newB and other immature and mature splenic B cell populations. 
C57BL/6 mice (age 4-5 weeks) were treated with initially 1 mg BrdU i.p. and 1 mg/ml BrdU in drinking 
water for 18 days. Groups of mice (n=5) were analysed at end of BrdU-labeling and after a chase period of 
21 days. Cells were isolated by FACS-sort with phenotypic markers to distinguish (u) transitional T1, (¯) 
transitional T2/3, () FOB, () MZB, (p) newB and (r) CD5+ cells. BrdU+ cells were detected with an 
intracellular anti-BrdU staining. 
NewB cells were labeled significantly higher than the other mature (CD19+ CD93-) B cells 
showing BrdU+ cell levels (80%) in-between the values obtained for T2/3 (88%) and MZB (57%) 
cells after the 18 days. Interestingly, after the 3 weeks chase period still 30% of the newB cells 
were BrdU+. 
The CD5+ cells, in contrast showed the lowest labeling kinetics of all analysed B cell populations 
in the spleen. 
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6.3 Discussion 
A putative new B cell population initially found in the spleen and to be of CD19+ CD93- CD21-/lo 
CD23-/lo phenotype could be further defined and characterized (6). The initially described 
population could be shown to be heterogeneous for CD5 expression. The CD5-/- subpopulation of 
cells, now termed newB cells (CD19+ CD93- CD21-/lo CD23-/lo CD5-), are small in size, comparable 
to FOB cells, and represent 2% of CD93- (mature) B cells in spleens of wild-type C57BL/6 mice. 
In contrast, cells of the CD5+ subpopulation (1%) are larger in size than the CD5- cells, have lower 
but more varied B220 expression levels (data not shown) and most probably comprise B-1a cells. 
The analysis of surface markers for B cell maturation, homing, adhesion and activation suggest that 
newB cells have overall a less mature phenotype. While Ig expression levels on newB cells are 
comparable to levels in MZB cells with a low and varied IgD expression but high IgM expression, 
CD19 and B220 expressions are slightly lower. Additionally, BAFF-R expression, known to be 
regulated by BCR signaling (10, 11), is slightly reduced, while the expression of CD24, described 
to be higher on less mature B cells (9), is elevated. Additionally, the TLR proteins CD180 and MD-
1, known to support signaling via the BCR and TLR4 in context of bacterial antigen, i.e. LPS (21) 
are expressed at lower levels. Compatible to these findings, activation markers such as CD25, 
CD44, CD80 and CD86 are not elevated on newB cells suggesting that newB cells do not represent 
activated B cells. Interestingly, CD62L, a L-selectin mediating lymphocyte homing to high 
endothelial venules of peripheral lymphoid tissue and to activated endothelium at inflammatory 
sites, is not expressed on newB and MZB cells, while FOB cells are CD62L+. This may indicate 
that newB cells represent a sessile B cell population, much as MZB cells. Alternatively, given the 
less mature phenotype, they do not fulfill criteria for re-circulation and, as a consequence, do not 
express CD62L. In addition, newB cells are negative for the surface markers CD5, CD9 and 
CD11b, that are all used in defining B-1 cell subpopulations. 
The findings of the analysis of λ1 light chain sequences demonstrated that newB cells are not 
subjected to somatic hypermutations and hence, most probably, do not belong to germinal center B 
cells and B cell memory. 
In functional assays newB cells did respond with cell proliferation to LPS, CpG and α-IgM + α-
CD40. However, the response to LPS and α-IgM + α-CD40 was significantly weaker than what 
was found for mature FOB and MZB cells, and even immature T2/3 cells showed a higher 
response. However, when stimulated with CpG, newB cells showed a response as strong as mature 
B cells. While CpG promote the proliferation of B cells via the TLR9 pathway, independently of 
the B cell receptor complex, signaling to LPS and α-IgM + α-CD40 in B cells does involve the 
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BCR complex. Therefore, it seems that triggering the BCR complex in newB cells leads only to an 
attenuated signal in these cells. In support of these findings were the results of an initial experiment 
measuring the Ca2+-flux in newB, FOB and MZB cells shortly after triggering the cells with a 
polyclonal α-IgM antibody. While a Ca2+-flux could be detected for MZB and FOB cells, it was 
not significantly detectable for newB cells (data not shown). It is therefore tempting to speculate 
that newB cells represent a population of anergic B cells, possibly as a consequence of carrying an 
autoreactive BCR. In order to test for this potential autoreactivity of cells of the newB cell 
population we produced hybridomas. Testing supernatants from individual newB cell-derived 
hybridomas in comparison to supernatants from FOB- and MZB-derived hybridomas though, did 
not show a higher frequency of auto-reactivity when tested on mouse kidney sections (data not 
shown). However these negative results are not finally conclusive, since the frequency of hybrids 
obtained only represent 0.1% of the B cells and also only less than hundred clones were tested from 
each subpopulation. Thus, it still remains possible that the new B cells represent an anergic B cell 
population. 
The findings, that newB cells show a relatively high turn-over (in between what was shown for 
transitional B and MZB cells) would be supportive of a theory that newB cells are less mature and 
are precursors of mature B cells. 
NewB cells were found in spleens of λ5-/- mouse in low numbers, however the proportion as 
compared to the total CD19+ cells is similar as in wild-type C57BL/6 mice (~2%). It seems 
therefore, that the rate of influx of immature B cells from the bone marrow does influence the 
development of cells with the newB cell phenotype only proportionally to other B-2 B cell subsets. 
In contrast, it was demonstrated that B-1 B cells develop to normal numbers in these mice either 
through an independent fetal precursor or, alternatively, through self-replenishment in the 
peritoneum (31). While both, Bcl-2 and BAFF over-expression lead to increased absolute numbers 
of newB cells in spleens of transgenic animals, the proportion of newB cells compared to the total 
CD19+ in Bcl-2 Tg animals did compare to normal C57BL/6 mice, whereas in BAFF Tg animals 
this proportion was reduced (~0.5%). However, the proportion of MZB cells is increased in these 
mice and it is highly speculative therefore, that newB cells might be involved in the development 
towards MZB cells. 
It is not yet clear, where newB cells could be placed precisely in the pathway along B cell 
development. However, a more detailed fingerprint emerged from the results of phenotypic 
analysis and functional assays. These cells show a generally less mature phenotype with a lower 
responsiveness to B cell stimuli (anergy), a relatively high turnover, while showing no evidence of 
belonging to the B cell memory or the B-1 B cell lineage. The collected data therefore supports the 
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idea that newB cells could represent an additional intermediate cell population in the transition of 
immature to mature B cells, or alternatively, newB cells could represent cells, which for as yet, 
unknown reasons get selected out from the pool of mature, reactive B cells later, because they do 
not fulfill criteria to remain and therefore are rendered anergic and regain a more immature 
phenotype. 
The latter concept could explain the somewhat conflicting finding that newB cells can also be 
found in lymph nodes. However, if these cells are selected out, it is difficult to understand, why 
these cells are not rapidly cleared from the circulation. Recently, our group observed a tremendous 
increase in the proportion of newB cells in spleens of very old mice. An observation, which 
indicates that newB cells are constantly acquired during adult B cell development and are therefore 
not of fetal origin.  
Nevertheless, the insight gained so far through this study should help in designing additional 
experiments eventually solving the mystery of this newly defined B cell subset. 
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7 DIFFERENTIAL RESPONSE OF MATURE SPLENIC B 
CELLS TO LPS IN C57BL/6 VERSUS BALB/C STRAIN 
OF MICE 
7.1 Introduction 
Gram-negative bacteria represent a major group of pathogens causing human diseases. The 
glycolipid lipopolysaccharide (LPS), also called endotoxin, is the principal bacterial component of 
the cell wall of all these pathogens and consists of a lipid A moiety, a core polysaccharide and an 
O-polysaccharide of variable length. Lipid A, which is responsible for the endotoxic effect, 
consists of a variable number of C12-14 fatty acids linked to a phosphorylated N-acetylglucosamine 
dimer. The composition and number of acyl side chains lead to different lipid A structures and 
explain the activation of differential signaling pathways depending on the origin of the 
lipopolysaccharide. Microbial variants with long O-polysaccharide chains form smooth colonies, 
whereas variants lacking the O-polysaccharide chain form rough colonies. All of these variants of 
LPS have implications for the host immune responses to Gram-negative bacteria (1-3). 
Recognition of LPS by various cell types of both the innate and the adaptive immune systems leads 
to pleiotropic cellular activation and responses with the ultimate goal to eliminate the invading 
pathogen. However, unregulated responses resulting in the release of an excessive amount of 
cytokines can lead to the pathological condition of septic shock and may eventually be fatal due to 
multiple organ failure. 
7.1.1 Toll-like receptors 
Although it is known already for many years how the adaptive immune system generates a broad 
and highly specific repertoire of antigen specific receptors, the faster responding innate immune 
system has been considered as being relatively unspecific, characterized by engulfment and 
digestion of microorganisms and foreign substances by macrophages and leukocytes. However, 
recent studies revealed that the innate immune system possess a higher degree of specificity. This 
became apparent with the discovery of a family of receptors, now known as the Toll-like receptors 
(TLRs), which recognize specific patterns of microbial components that are conserved among 
pathogens. Originally the Toll receptor was identified in Drosophila as an essential receptor for the 
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dorso-ventral patterning in embryos (4). Later, while analyzing Toll-mutant flies, it was discovered 
that they where highly susceptible to fungal infections. This study revealed, for the first time, that 
the immune system, particularly the innate immune system, could detect invading microorganisms 
using structures different from the B and T cell receptors of the adaptive immune system (5). 
Subsequently, mammalian homologues (TLRs) of the Drosophila Toll receptor where identified. 
They include at least 11 type I integral membrane glycoproteins and are members of a larger 
superfamily including the IL-1 receptor (6). 
The cytoplasmic portion of TLRs has high similarity to that of the IL-1 receptor family and is 
therefore called Toll/IL-1 receptor (TIR) domain. The TIR domain binds to adaptor molecules 
involved in downstream signaling pathways. Unlike the Ig-like extracellular domain of IL-1 
receptors, the extracellular domain of TLRs contains leucine-rich repeats (LRRs) and interacts 
specifically with microbial components. 
After ligand binding and crosslinking of the TLRs, signaling originates from the cytoplasmic TIR 
domains. A TIR-domain containing adaptor protein, MyD88, which was first characterized to be 
utilized in IL-1R signaling has been shown to be also involved in TLR signaling (7, 8). It is now 
recognized that, at least, TLR signaling pathways consist of a MyD88-dependent pathway common 
to all TLRs and a MyD88-independent pathway that is especially involved in the TLR3- and TLR4 
signaling pathways (9). 
7.1.1.1 MyD88-dependent pathway 
MyD88 associates with the TIR domain of TLRs or in the case of TLR2 and TLR4 via the adaptor 
protein TIRAP (10, 11). Upon receptor stimulation the homodimeric MyD88 recruits IL-1 receptor 
kinase-1 (IRAK1), which gets activated by phosphorylation through IRAK4, and then associates 
with tumor necrosis factor receptor (TNFR)-associated factor-6 (TRAF6). The IRAK1-TRAF6 
complex is released from the receptor complex and forms a complex with TGF-β-activated kinase 
1 (TAK1) and the TAK1-binding proteins TAB1 and TAB2. TAK1 activates NF-κB-inducing 
kinase (NIK), which leads to NF-κB activation as well as the JNK and p38 MAPK pathways, 
which activate AP-1 complexes. NF-κB and AP-1 enter the nucleus where they activate the 
transcription of inflammatory genes, particularly cytokines (Figure 1). 
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Figure 1 . TLR4 and TLR9 signaling pathways. 
TLR4 signaling in response to LPS includes the MyD88-dependent and MyD88-independent pathways. 
Intracellular TLR9 signaling is MyD88-dependent. 
TIR (Toll/IL-1 receptor domain), LBP (LPS binding protein), IRAKs (IL-1 receptor kinases), IRF3 
(Interferon regulatory factor 3), TAB1,2 (TAK1-binding proteins), TAK1 (TGF-β-activated kinase), TRAF6 
(TNFR-associated factor 6), TRAM (TRIF-related adaptor molecule), TRIF (TIR-domain adapter inducing 
IFN-β), TRK1 (TANK-binding kinase 1) 
7.1.1.2 MyD88-independent pathway 
Stimulation of TLR3 or TLR4 results in the induction of type I interferons (IFN-α/β) in a MyD88-
independent manner. This pathway depends on the adaptor protein TIR domain-containing adapter 
inducing IFN-beta (TRIF) (12). In MyD88-independent signaling through TLR4 an additional 
adapter protein, TRAM, bridges TLR4 to TRIF in a similar fashion as TIRAP for MyD88-
dependent signaling through TLR4 (13). Signaling through TRIF-TRAM leads to the activation of 
the non-canonical IκB kinases (IKKs), TANK-binding kinase 1 (TBK1) and IKKε/IKKi, as well as 
the IFN-inducible protein kinase PKR. The actions of these kinases result both in NF-κB 
DIFFERENTIAL RESPONSE OF SPLENIC MATURE B CELLS TO LPS CHAPTER 7 
   
 
 
122 
activation, enhancing the transcription of inflammatory cytokines, and the activation of STAT1 and 
IRF-3 and induction of both IFN-β and IFN-inducible genes (14-16) (Figure 1). 
7.1.2 The role of TLR4 in response to lipopolysaccharides (LPS) 
It has been shown, that after microbial infection, LPS is bound by LPS-binding circulating protein 
(LBP) in the plasma and can be recruited to the pattern recognition receptor CD14, which is present 
in the plasma as well as on the cell surface of mononuclear phagocytes (17, 18). However the GPI-
anchored CD14 is missing a cytoplasmic signaling domain and other cells like B cells hardly 
express CD14 but respond to LPS. The identification of a membrane receptor involved in signaling 
to LPS was facilitated by the existence of LPS-resistant mouse strains [C3H/HeJ, C57BL/10ScCr 
and C57BL/10ScN]. By analyzing these strains it was found that allelic mutations of a single locus, 
then called LPS locus, were shown to abrogate the response to LPS (19-22).  Later on, positional 
cloning identified the tlr4 gene as the only candidate gene in the LPS locus (23). The generation of 
a TLR4 knockout mouse further confirmed the essential role of TLR4 in LPS responsiveness (24). 
Furthermore it could be shown that the TLR4 expression level determines the degree of LPS-
susceptibility as by B cell mitogenicity, cytokine induction and lethal toxicity (25). However, 
transfection of cell lines with TLR4 did not enable these cell lines to respond to LPS, suggesting 
that yet another factor links TLR4 to LPS signaling. MD-2, a secreted protein, was then shown to 
associate with TLR4 and functions as an adaptor for LPS recognition thus defining the TLR4/MD-
2 complex as the LPS signaling receptor. In addition, MD-2 functions as a chaperone guiding 
TLR4 through maturation to the plasma membrane as absence of MD-2 abolishes surface 
expression of TLR4 (26-28). 
7.1.3 TLR4 signaling in B cells 
The majority of work on TLR and TLR signaling in mammalian cells has been done in the context 
of dendritic cells and monocytes/macrophages. In recent years, studies have specifically examined 
the TLR expression in B cells. The majority of TLRs in human B cells upregulate their expression 
upon activation. Although, these studies mainly focused on human B cells, the results presented 
were presumed to extend to rodent B cells. However, there is evidence that species specific 
differences exist as naïve B cells from mice are known to express TLR4 and undergo proliferation 
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and plasmacytoid differentiation in vitro in response to LPS, while human B cells seem to lack 
significant TLR4 expression in either naïve or memory B cells (29-32). In the search for 
monoclonal antibodies with radioprotective activity with the initial goal to identify receptors on B 
cells, which control apoptosis, a 105kDa molecule, referred to as RP105 (CD180), has been found. 
Originally it was found that RP105 expression is restricted to mature B cells, but later been shown 
to be also expressed in monocytic and dendritic cells. A structural analysis revealed that RP105 
belongs to the family of Toll-like receptors. But unlike other TLR family members, RP105 does 
not contain a cytoplasmic TIR domain (33, 34). For efficient cell surface expression RP105 needs 
the coexpression of the MD-2 homologous protein MD-1 (35). The stimulation of mature B cells 
with an anti-RP105 Ab induced their proliferation and blastogenesis. While B cells of TLR4-/- or 
MD-2-/- mice do not respond to LPS, RP105-/- or MD-1-/- mice show reduced responses to LPS. 
Furthermore in a NF-κB reporter assay expressing TLR4 and RP105/MD-1 together an increased 
response to LPS was measured compared to cell lines expressing TLR4/MD-2 alone suggesting 
that these receptors act synergistically in B cells. In contrast to the situation in B cells, RP105 
seems to have an inhibitory role in TLR4 signaling in monocytic and dendritic cells (DCs) and 
macrophages and DCs from RP105-/- or MD-1-/- mice do not show a reduced response to LPS 
indicating that there are differences in signaling between B cells and macrophages or DCs in the 
response to LPS (33, 36-38). It could be shown that RP105 activates similar pathways to B cell 
receptor signaling such as the Lyn/CD19/Vav complex, the PI 3-kinase, Btk, and other molecules 
of the B cell receptor (BCR) signalosome. LPS binding to RP105 induces Lyn activation and 
phosphorylation of CD19, which in turn augments the Lyn kinase activation. The PI 3-kinase and 
Btk are activated independently of CD19 and regulate intracellular calcium flux in response to 
RP105 signaling. As the cytoplasmic domain of RP105 is only 11 aa, it has been suggested that 
RP105 acts by recruiting signaling components into rafts and thereby facilitating signaling to LPS. 
It could be shown that RP105 induces the CD19 translocation into lipid rafts together with the 
constitutively lipid raft-located Lyn (39, 40). Moreover, as RP105 activates similar pathways to 
BCR signaling that might directly link innate and adaptive immunity in B cells. Nevertheless, the 
precise mechanism how RP105 and TLR4 might cooperatively regulate responses to LPS in B cells 
is still unclear (Figure 2). 
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Figure 2. TLR4 signaling in B cells. 
TLR4 signaling to LPS in B cells involves RP105 and integrates components of the BCR-signalosome 
(Modified, adapted from (40)). 
7.1.4 TLR9 mediates signaling in response to CpG 
Unlike TLR4, members of the TLR9 subfamily (TLR7, 8, 9) sense pathogen-derived RNA and 
DNA motifs generated during intracellular infections. TLR9 is expressed intracellularly in the 
endosomal-lysosomal compartment and detects hypomethylated CpG motifs. Upon non-specific 
cellular uptake of CpG-ODN into the acidified endosomal compartment, either through 
internalization or generated due to an intracellular infection, TLR9 directly binds sequence 
specifically and initiates signaling in a MyD88-dependent fashion (Figure 1) (32). 
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7.1.5 Response of mature B cells to the mitogens LPS and CpG in mice of 
different genetic backgrounds 
It has been shown that frequencies of mitogen-reactive B cells in mice of different genetic 
background differ. Limiting dilution experiments showed that 1 out of 6 splenocytes of a C57BL/6 
mouse responded to LPS, while in the spleen of BALB/c mice only 1 in 20 cells responded (41). 
However, at this time the knowledge about the different B cell compartments in the spleen was still 
very limited. In addition, the pattern recognition receptors (PRRs), including the TLRs were not yet 
identified. 
We investigated the responsiveness of the major splenic mature B cell populations comprising the 
follicular B (FOB: CD19+ CD93- CD21+ CD23+) and marginal zone B (MZB: CD19+ CD93- 
CD21hi CD23-/lo) cells from mice of different genetic backgrounds to LPS and CpG in vitro. 
Furthermore, we tried a genetic approach in order to help understanding the differences in 
responsiveness of mature B cells in mice of different genetic backgrounds, as well as between FOB 
and MZB cells. 
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7.2 Results 
7.2.1 Reactivity of follicular B cells stimulated in vitro with LPS and CpG 
Splenic mature B cells of FOB (CD19+ CD93- CD21+ CD23+) phenotype were isolated from 
spleens of young adult mice of either C57BL/6 or BALB/c strain by FACS sorting. The cells were 
stimulated in vitro either with the TLR4 ligand LPS or the TLR9 ligand CpG. To avoid signaling 
through other TLRs, like TLR2 as a consequence of lipoprotein-contaminants, purified, phenol-
extracted LPS was used (42). TLR9 detects microbial DNA with hypomethylated CpG motifs. 
Unlike TLR4, which is expressed on the cell surface, TLR9 is expressed in the endoplasmic 
reticulum and signals from an endosomal compartment upon CpG DNA internalization (43).  
The reactivity of the cells to these stimuli was measured after 3 days of culture by means of their 
[3H]thymidine uptake into DNA of proliferating cells. 
 
Figure 3. Stimulation of sorted FOB cells (C57BL/6 and BALB/c strains) with lipopolysaccharide 
(LPS) or CpG 
(A) LPS [0-50µg/ml] or (B) CpG (CpG1826 [0-12.5 µg/ml]) for 72h. Measurement of [3H]thymidine uptake 
for the last 9h of culture. Control: unstimulated cells. 
After in vitro LPS induced activation, FOB cells of C57BL/6 mice show a significantly higher 
level of [3H]thymidine uptake than those of the BALB/c mouse strain at all concentrations of LPS 
tested. 
However, when FOB cells were stimulated with CpG, the proliferative response was more vigorous 
than with LPS, but both strains responded equally strong. Thus, the difference observed between 
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the two strains in their response of FOB cells to LPS might involve components of the TLR4 
pathway, which are not shared with the TLR9 signaling pathway. 
7.2.2 Expression levels of TLR4/MD-2 and RP105/MD-1 in C57BL/6 strain 
compared to BALB/c strain 
B cells have a non-redundant requirement for the expression of the LPS receptors TLR4 and 
RP105, which both function as recognition and signal transducing receptors. TLR4 is ubiquitously 
expressed in leucocytes, but compared to macrophages and dendritic cells, B cells express 
relatively little TLR4. In contrast, the expression of RP105 (CD180) is more limited to mature B 
cells (34, 44), which includes FOB cells. In a first attempt to test whether the differences in LPS 
reactivity seen in FOB cells of the two mouse strains is simply a result of different expression 
levels for the receptors TLR4 and RP105 together with their adaptors MD-2 and MD-1, 
respectively, the level of transcripts of these components were measured in sorted FOB cells using 
semi-quantitative RT-PCR. In addition the level of TLR9 transcripts was also determined. 
Figure 4. Transcript levels of LPS 
and CpG receptor components in 
FOB cells 
Semi-quantitative RT-PCR analyses of 
the transcript levels for the LPS 
receptor components TLR4, MD-2, 
RP105, MD-1 and the CpG receptor 
TLR9 in sorted FOB cells. As internal 
standard, the transcript level of β-actin 
was included. 
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Some differences in transcript levels were detected for TLR4 and RP105. While TLR4 showed a 
higher level in FOB cells of the C57BL/6 strain, RP105 showed a higher level in FOB cells of the 
low responder strain BALB/c. However, both adaptor molecules, MD-2 for TLR4 and MD-1 for 
RP-105 were detected with similar levels in both strains. Given the fact that complexes of these 
molecules are expressed in 1:1 ratios for the functional receptors with their adaptors it is, however, 
not clear how that determines the final LPS stimulation (Figure 4). 
As expected from the results obtained by stimulating the cells with CpG, no difference in the 
transcript level for TLR9 could be detected for the two mouse strains (Figure 4, upper part). 
Additionaly, the surface expression of TLR4 / MD-2, RP105 and MD-1 on purified mature B cells 
from C57BL/6 and BALB/c mice was determined by FACS. Splenocytes were depleted for CD5+ 
cells, such as B1-a B cells and T cells, and immature transitional CD93+ B cells by MACS. The 
remaining cells were stained for B220, CD21 and CD23 in combination with antibodies specific 
either for TLR4/MD-2, RP105 or MD-1. This allowed for distinguishing the FOB (B220hi CD21+ 
CD23+) and the MZB cells (B220hi CD21hi CD23-/lo). 
TLR4/MD-2 was detected only weakly on the surface of FOB and MZB cells by FACS. RP105 and 
MD-1 are expressed on both FOB and MZB cells from C57BL/6 and BALB/c mice. However, 
there is only a very small shift seen between the two strains, which can hardly explain the 
difference seen in LPS responsiveness of the FOB cells. Interestingly, the surface expression levels 
of RP105 and MD-1 as calculated from the mean fluorescence intensities (MFI) are 3.1-3.5 times 
higher on MZB compared to FOB cells for both strains, an observation, which has also been 
described, at least for RP105, by others (45-47) (Figure 5). 
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Figure 5. Surface expression of TLR4/MD-2 and RP105/MD-1 in FOB and MZB cells of C57BL/6 and 
BALB/c mice. 
Splenocytes from adult C57BL/6 and BALB/c mice (pools of 3 spleens/strain) were MACS-depleted for 
CD5+ and CD93+ cells. Remaining cells were stained for B220, CD21 and CD23 in combination either for 
TLR4/MD-2, RP105 or MD-1. (A) Mature B cell populations after MACS-depletion. (B) TLR4/MD-2, 
RP105 and MD-1 surface expression on FOB (B220hi CD21+ CD23+) and MZB (B220hi CD21hi CD23-/lo) 
cells of C57BL/6 and BALB/c mice. (C) Mean fluorescence intensities (MFI) for RP105 and MD-1 surface 
expression. 
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7.2.3 Kinetics of in vitro LPS-stimulated FOB cells: C57BL/6 versus BALB/c 
strain 
Sorted FOB cells from C57BL/6 and BALB/c strains were loaded with CFSE (Carboxyfluorescein 
succinimidyl ester) and cultured in vitro in the presence of LPS [5µg/ml] for 1 week. Every 0.5-1 d 
sample of cells were analysed for the content of CFSE and viability (PI) by FACS. 
 
Figure 6. Kinetics of LPS-stimulated FOB cells in vitro: C57BL/6 versus BALB/c strain 
For panel B and description see next page. 
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Figure 6. Kinetics of LPS-stimulated FOB cells in vitro: C57BL/6 versus BALB/c strain 
Sorted FOB cells from C57BL/6 and BALB/c strain (from pooled splenocytes of 3 mice per strain) were 
loaded with CFSE and stimulated in culture (1x105 cells/96-well) with [5µg/ml] lipoprotein-free LPS and 
analysed (gated for life cells) at intervals of 0.5-1 d. (A) The decrease in CFSE levels (filled grey: 
unstimulated cells) and (B) the percentage of viable cells (PI) was monitored over time.  
FOB cells of C57BL/6 strain stimulated with LPS responded quicker (approx. 0.5 d) than of the 
BALB/c strain. They also responded more vigorously and show 6-7 divisions by day 4, while cells 
of the BALB/c strain proliferated one generation less (Figure 6). 
7.2.4 Response of MZB cells from C57BL/6 and BALB/c mice to LPS 
As FOB cells show a differential reactivity to LPS in the two, tested mouse strains the reactivity of 
the less abundant marginal zone B (MZB) cells was also tested. MZB cells (CD19+ CD93- CD21hi 
CD23-/lo) were isolated from spleens of young adult mice by FACS. The cells were stimulated in 
vitro with lipoprotein-free LPS and the reactivity was measured as [3H]thymidine uptake into DNA 
of proliferating cells. 
Interestingly, MZB cells of both mouse strains show a similar strong proliferative response to LPS 
(Figure 7). Compared to FOB cells the response is stronger and starts earlier as has been seen by 
the visual appearance of blasts in the cultures within 24 h. This has been also confirmed by others 
(data not shown; (45, 48, 49)) and could be explained, at least in part, by the higher expression 
levels of RP105 and MD-1 on MZB cells (Figure 5B and C). Furthermore, it has been recently 
shown that MZB cells possess an enhanced secretory apparatus including a more abundant rough 
endoplasmatic reticulum, which enables MZB to react rapidly to bacterial components like LPS 
(45). 
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Figure 7. Stimulation of sorted MZB cells (C57Bl/6 and BALB/c strains) with lipopolysaccharide (LPS) 
Sorted cells were cultured in the absence (control) or presence of LPS [10µg/ml] for 72h. [3H]thymidine 
uptake during the last 9h of culture was recorded. 
However, this raises the question if some of the components involved in signaling through the 
TLR4 pathway are differentially expressed. 
7.2.5 Genetic approach: responsiveness of FOB cells from intercrosses and 
backcrosses 
A genetic approach was set up with the ultimate goal to identify the locus responsible for the 
differential response of FOB cells to LPS in the two mouse strains. With the data so far known 
from others and obtained through our in vitro proliferation assays one could have expected to find a 
component involved in the TLR4 signaling pathway. By generating F1 (BALB/c x C57BL/6) 
hybrid animals and backcrossing them on either the C57BL/6 or BALB/c strain and considering the 
Mendelian law of genetics we expected to receive low and high responder mice in terms of the 
proliferative response of their FOB cells to LPS. With the help of existing microsatellite markers 
(polymorphism) for the C57BL/6 and BALB/c strain it would then be possible to identify the 
responsible locus. 
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7.2.5.1 Response of FOB cells from F1 (BALB/c x C57BL/6) animals to LPS 
FOB cells from C57BL/6, BALB/c and from F1 (BALB/c x C57BL/6) hybrid young adult (6-8 
weeks) mice were stimulated with LPS for three days in vitro. The proliferative response of the 
FOB cells isolated from F1 (BALB/c x C57BL/6) hybrid mice was exactly in between (50%) the 
values obtained for C57BL/6 (100%) and BALB/c animals (26%) (Figure 8). This might indicate 
that components necessary for the LPS induced proliferative response are limiting in the FOB cells 
of the BALB/c strain and that is only partly restored by one allele from the high responder strain 
C57BL/6. However, new F1 animals, where the mother is C57BL/6 could be tested in addition to 
test for a possible effect of maternal imprinting. 
 
 
Figure 8. Response of FOB cells to LPS from F1 (BALB/c x C57BL/6) animals 
Sorted cells were cultured in the absence (control) or presence of LPS [5µg/ml| for 72h. [3H]thymidine 
uptake during the last 9h of culture was recorded. 
7.2.5.2 Response of FOB cells from F2 BALB/c x (BALB/c x C57BL/6) backcrosses 
to LPS 
FOB cells sorted individually from F2 BALB/c x (BALB/c x C57BL/6) offsprings were stimulated 
for three days in vitro with LPS. As a high responder control (100%) sorted FOB cells from a 
C57BL/6 mouse were used. The results obtained show a more complex picture with responses over 
a wide range (9-56%) but mostly staying below half of the proliferative response of FOB cells from 
the C57BL/6 high responder strain (Figure 9A). This is contrary to what one expects for a one-
locus event responsible for the difference in responses observed earlier in the F1 animals, where 
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now in the F2 generation one would expect segregation into low and intermediate responders. 
However, keeping in mind that multiple loci might be involved, that could explain the observed 
results. Therefore a backcross of the F1 animals onto the high responder C57BL/6 strain should at 
least show an overall higher response of the FOB cells to LPS in these mice considering a locus 
dosage effect. 
 
Figure 9. LPS response of FOB cells from F2 animals 
(A) F2 BALB/c x (BALB/c x C57BL/6); MZB: pooled from animals 11-20. 
(B) F2 C57BL/6 x (BALB/c x C57BL/6). 
Sorted cells were stimulated with LPS [5µg/ml] for 72h. [3H]thymidine uptake was determined during the 
last 9h of the culture. Control: unstimulated cells. 
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7.2.5.3 Response of FOB cells from F2 C57BL/6 x (BALB/c x C57BL/6) backcrosses 
to LPS 
When FOB cells were sorted from individual spleens of the other F2 breeding, C57BL/6 x 
(BALB/c x C57BL/6), and stimulated with LPS, FOB cells from all individual F2 animals showed 
indeed overall higher proliferative responses (59-84%) (Figure 9B). Therefore, the results indicate 
that multiple genes might control the response of FOB to LPS in C57BL/6 and BALB/c strains in a 
differential fashion. Alternatively, a single gene for the component limiting LPS responses in 
BALB/c might be subject to maternal imprinting when the mother is a high responder. However, 
for both of these backcrosses, more animals have to be tested including controls of F1 FOB cells. 
7.2.6 Influence of the MyD88-dependent pathway 
TLR signaling pathways consist of a MyD88-dependent pathway common to all TLRs and a 
MyD88-independent pathway involved in the TLR3- and TLR4 signaling pathways (9). The 
current view is that LPS responsiveness of B cells is mainly mediated through the MyD88-
dependent pathway. To address the role of the MyD88-dependent pathway in the different outcome 
of LPS-stimulated FOB cells in the two different mouse strains and to exclude that the effect 
observed is not due to a contribution of the MyD88-independent pathway, we analysed mature B 
cells of MyD88-deficient animals of either C57BL/6 or BALB/c background. 
FOB cells sorted from C57BL/6, BALB/c, C57BL/6 MyD88-/- and BALB/c MyD88-/- young adult 
(6-8 weeks) mice were stimulated with different LPS concentrations [1-25µg/ml] during three days 
in vitro. The proliferative response of the cells was again determined by [3H]thymidine uptake into 
the DNA. 
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Figure 10. Proliferation of FOB cells from normal or MyD88-deficient mice of C57BL/6 and BALB/c 
background. 
Sorted cells were stimulated with LPS (A): [0-25 µg/ml (A)] for 72h or (B): [5µg/ml (B)] including MZB 
cells of MyD88-/- mice for 72h. [3H]thymidine uptake was determined during the last 9h of the culture. 
Control: unstimulated cells. 
As expected, FOB cells from MyD88-/- animals of both backgrounds showed a reduced 
proliferative response to LPS. However, in contrast to wild-type BALB/c mice, FOB cells from 
MyD88-/- animals with BALB/c background showed even a slightly higher proliferative response 
than from MyD88-/- animals of C57BL/6 background (Figure 10A). In addition, MZB cells from 
MyD88-/- mice of BALB/c background still showed a proliferation as strong as normal FOB cells 
of BALB/c strain (Figure 10B). 
Based on these results one might assume that the difference seen in LPS reactivity between FOB 
cells of C57BL/6 and BALB/c strains must either involve components within the MyD88-
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dependent pathway or involves components, which can modulate the MyD88-dependent signaling 
pathway. 
7.2.7 Is differential responsiveness to LPS due to the haplotype of the MHC 
class II locus ? 
Recently, Rodo et al. (50) investigated also the differential response of mature B cells to LPS in 
C57BL/6 and BALB/c mice. They claim to have located the MHC class II locus to be responsible 
and therefore that the d haplotype of the BALB/c strain leads to a lower responsiveness of mature 
B cells to LPS in this strain. However, in their study total B220+ B cells were used without 
distinguishing the FOB and MZB cell compartments, which show different reactivity to LPS and 
are actually represented in slightly different ratios in C57BL/6 and BALB/c mice. Nevertheless, to 
test their results, we analysed the response to LPS and CpG stimulation of FOB and MZB cells 
from BALB/b mice. BALB/b differ from BALB/c mice only in the MHC, where the b haplotype is 
present, which they share with the high responder C57BL/6 strain. Therefore, according to the 
claim of Rodo et al. one would expect a similar response for FOB cells of BALB/b and C57BL/6 
mice. Sorted FOB and MZB cells from C57BL/6, BALB/c and BALB/b mice were stimulated with 
LPS for three days in vitro and the proliferative response was measured by [3H]thymidine uptake 
into DNA of proliferating cells. 
Interestingly, FOB cells from the BALB/b strain showed a low response similar to FOB cells from 
the BALB/c strain (Figure 11A). This is in contrast to what one could have expected for the b 
haplotype, if the MHC haplotype is responsible for the outcome of LPS-stimulated FOB cells. 
LPS-stimulated MZB cells from the three strains proliferated to a very similar extent (Figure 11B). 
Likewise, FOB cells stimulated with CpG responded equally strong in all three strains tested 
(Figure 11C). 
In addition, the level of CD69 surface expression on FOB cells was addressed in the absence or 
presence of LPS on in vitro cultured FOB cells from C57BL/6, BALB/c and BALB/b mice. The 
expression of the common early lymphocyte activation marker CD69, a c-type lectin, is augmented 
shortly after the activation of lymphocytes (51). For this, sorted FOB C57BL/6, BALB/c and 
BALB/b mice were cultured in the absence or presence of LPS. After 24h of culture the expression 
of CD69 was only elevated on LPS-stimulated FOB sorted from C57BL/6 mice (Figure 11D). 
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We suggest therefore, that the difference seen between C57BL/6 and BALB/c derived LPS-
stimulated FOB cells is unlikely to be principally determined by the MHC class II haplotype of 
these strains. 
 
Figure 11. Proliferation and CD69 surface expression of sorted FOB and MZB cells (C57BL/6 versus 
BALB/c and BALB/b strains) in response to LPS and CpG stimulation  
Sorted FOB (A) or MZB (B) cells were stimulated with LPS [5µg/ml] for 72h. In addition, FOB cells were 
also stimulated with CpG [0.5µg/ml] (C). Measurement of [3H]thymidine uptake during the last 9h of the 
experiment. 
(D) Surface expression of CD69 (MFI) on unstimulated and LPS-stimulated FOB cells ([5µg/ml] for 24h in 
vitro). 
(A-D) FOB and MZB cells sorted from pooled splenocytes (spleens: n=3 for each strain); cultures: 1x105 
cells/96-well (n=3). Control: unstimulated cells. 
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7.3 Discussion 
A variety of mitogenes, many of them are bacterial components, stimulate murine B lymphocytes 
polyclonally to proliferate and to differentiate into Ig-secreting plasma cells. 
It was known that frequencies of LPS-reactive B cells from C57BL/6 and BALB/c mice differ 
showing a higher frequency in C57BL/6 mice (41). However, at this time little was known about 
the different B cell compartments within the spleen and many receptors for mitogenes, members of 
the Toll-like receptor family  (TLRs), were not yet identified.  
Here, distinguishing the two most abundant, mature B cell types present in the spleen, follicular  B 
(FOB) and marginal zone B (MZB) cells, we could show that actually the FOB cells of C57BL/6 
respond stronger to LPS than FOB cells of the BALB/c strain. 
The unique location of MZB in close proximity to the marginal sinus in the spleen makes them 
ideally suited to respond to blood-borne antigens, like gram-negative, LPS -containing bacteria. In 
line with that, MZB cells adapted themselves to respond earlier and stronger to LPS than the more 
abundant recirculating FOB cells. MZB cells allocate an enhanced secretory apparatus with a more 
abundant rough endoplasmatic reticulum than FOB cells (45, 49). Additionally, MZB cells show a 
3-4 times higher expression of the TLR proteins RP105 and MD-1 compared to FOB cells. Both 
proteins were shown to support the response of B cells to LPS. In this comparative study, MZB 
cells of both mouse strains showed a stronger response to LPS than the FOB cells. However, in 
contrast to the observation in FOB cells, MZB cells of both tested strains responded equally strong. 
Having observed the stronger response of FOB cells from C57BL/6 mice an obvious question was, 
as to what extent expression levels of the LPS receptor molecules might vary between FOB cells of 
C57BL/6 and BALB/c strains. However, TLR4 / MD-2 expression levels could not be measured to 
be significantly different between the two strains. Additionally, while expression levels for RP105 
and MD-1 were found to be 3-4 higher on MZB cells compared to FOB cells within both strains, 
the differences between the strains for both cell types were minimal.  
Given the complexity of the TLR4 signaling pathway we tried a genetic approach. By generating 
F1 hybrid animals and backcrossing those onto either parental strain, we expected to obtain low 
and high responder animals and aimed at a genetic screening approach with the help of 
microsatellite markers (polymorphism) to possibly identify a responsible locus. We found that FOB 
cells from F1 animals responded with values exactly half of what was found for the parental 
strains. FOB cells of F2 BALB/c x (BALB/c x C57BL/6) backcross animals, however, showed 
responses below half of the response of the high responder FOB cells from C57BL/6 mice, while 
FOB cells from C57BL/6 x (BALB/c x C57BL/6) animals showed an overall higher response than 
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FOB cells from F1 animals. However, results from either backcrosses did not segregate into low 
and intermediate responders or intermediate and high responders, respectively. 
Therefore, the results indicate that multiple genes control the response of FOB cells to LPS in 
C57BL/6 and BALB/c strains in a differential fashion. Given the complexity of the expression 
network with induction and repression of expression in a temporal cascade upon engagement of the 
LPS-receptor components, the results from the genetic approach are not completely surprising. To 
get more insight, many more animals need to be tested. An alternative approach to get more insight 
could involve the collection and analysis of temporal oligonucleotide microarray data during the 
response of FOB cells to LPS for the two strains. 
However, alternatively, still, a single gene for the component limiting LPS responses in BALB/c 
might be subject to maternal imprinting when the mother is a high responder. This could be tested 
by breeding F1 animals for which the mother would be of the C57BL/6 strain.  
While all TLRs rely on a MyD88-dependent pathway, signaling through TLR3 and TLR4 
additionally involves a MyD88-independent pathway (9). Analysing the response to LPS of FOB 
cells from MyD88-deficient animals of both C57BL/6 and BALB/c backgrounds showed, that in 
absence of MyD88, the response of FOB cells of C57BL/6 background is strongly reduced, being 
even slightly weaker than for FOB cells of BALB/c background. This suggests that the stronger 
response of wild-type FOB cells of C57BL/6 either involves components of the MyD88-dependent 
pathway, or alternatively, components that modulate the MyD88-dependent pathway. 
In contrast to stimulation with LPS, treatment with CpG led to a similar response of FOB cells of 
both strains and therefore supports the idea that the differential outcome to LPS is independent of 
components shared with the TLR9 pathway.  
Investigations of another group claimed to have located the MHC class II locus to be responsible 
for the different strength of responses of mature B cells from C57BL/6 and BALB/c mice to LPS 
stimulation (50). They have identified the d haplotype of the BALB/c strain to be responsible for 
the lower response of mature B cells in that strain. However, the results presented were based on 
the analysis of total splenic B220+ cells. To test their results we included the analysis of FOB and 
MZB cells from BALB/b mice, which differ from BALB/c mice in that they share the b haplotype 
with the C57BL/6 strain. In contrast to what was found by Rodo et al, FOB cells from the BALB/b 
b haplotype strain showed a similar low response as FOB cells from the BALB/c d haplotype 
strain. Additionally, MZB cells of all three tested mouse strains showed similar responses to LPS 
and CpG. We conclude, therefore, that the MHC class II haplotype is not a major contributor to the 
different strength of responses seen for FOB cells of the tested strains. 
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This work identified the FOB cells of C57BL/6 and BALB/c to respond with different strength and 
is dependent on the MyD88-dependent signaling pathway. It remains intriguing, why this effect 
could not be seen in MZB cells. Either the modulating components are additionally differentially 
regulated between FOB and MZB cells, or alternatively, the observed effect does not become 
apparent in MZB cells as these cells already respond stronger than FOB cells. However, given the 
abundance of FOB cells in the mouse, this effect must have a different overall impact in the 
response of the adaptive immune system upon challenges with LPS containing bacteria in the two 
tested mouse strains. 
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Abbreviations 
Ab Antibody 
ADCC Antibody-dependent cellular cytotoxicity 
Ag Antigen 
APC Antigen presenting cell 
BAFF B cell activating factor of the TNF family 
BAFF-R BAFF receptor 
Bcl-2 B cell leukemia 2 (oncogene) 
BCR B cell receptor 
BM Bone marrow 
bp Base pair 
BrdU 5-bromo-2’-deoxyuridine 
BSAP B-cell-specific activator protein 
C region Constant region 
CD Cluster of differentiation 
cDNA Complementary DNA 
CFSE Carboxyfluorescein succinimidyl ester 
CLP Common lymphoid progenitor 
CpG ODN Oligodeoxynucleotides containing unmethylated CpG motifs 
D region Diversity region 
DC Dendritic cell 
E2A Transcription factor E2A 
EBF Early B cell factor 
FACS Fluorescence-activated cell sorter 
FOB Follicular B cell 
HMG High mobility group protein 
IFN Interferon 
Ig Immunoglobulin 
IgH Immunoglobulin Heavy-chain 
IgL Immunoglobulni Light-chain 
IKK IκB kinase 
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IL Interleukin 
IRAK IL-1 receptor kinase 
ITAM Immune tyrosine activation motif 
ITAM Immune tyrosine activation motif 
J region Junctional region 
LBP LPS-binding protein 
LN Lymphnode 
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinase 
MHC Major histocompatibility complex 
MZ Marginal zone 
MZB Marginal zone B cell 
MZM Marginal zone macrophage 
NF-κB Nuclear Factor kappa B 
NHEJ Nonhomologous end joining 
PALS Periarteriolar lymphoid sheath 
PAX Paired box transcription factors 
PC Phosphorylcholine 
PCR Polymerase chain reaction 
PI Propidium iodide 
PKR Protein kinase R 
Pre-B Pre-B cell 
Pre-BCR Pre-B cell receptor 
Pre-TCR Pre-T cell receptor 
PtC Phosphatidyl choline 
RAG Recombination activating gene 
RSS Recombination signal sequences 
RT Room temperature 
RT-PCR Reverse transcriptase polymerase chain reaction 
SL chain Surrogate light chain 
T1/2/3 Transitional 1/2/3 cells 
TAB TAK-binding protein 
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TAK TGF-β-activated kinase 
TBK TANK-binding kinase 
TCR T cell receptor 
TdT Terminal deoxynucleotidyl transferase 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRAF-6 TNF receptor-associated factor 6 
TRAM TRIF-related adaptor molecule 
TRIF TIR domain-containing adapter inducing IFN-beta 
TSLP Thymic stromal lymphopoietin 
TSLP-R Thymic stromal lymphopoietin receptor 
V region Variable region 
WT Wild type 
 
  CURRICULUM VITAE 
   
 
149 
Curriculum vitae 
Personal data  
Name Lukas Andreas Flück 
Date of birth 20.02.1971 
Place of birth Basel 
Place of citizenship Brienz/BE 
Nationality Swiss 
Address Pfeffingerstrasse 12D 
CH-4147 Aesch 
  
Education  
1978 - 1987 Primary and Secondary School, Aesch/BL 
1987 - 1991 Grammar school, Muenchenstein/BL 
Degree: Matur (Typus C) 
10/1992 – 5/2002 Federal Institute of Technology Zurich (ETHZ): Diploma in 
biochemistry 
Title of diploma thesis: ‘Putative role of RNP1- and RNP2-
sequence elements for the antiviral function of mouse Mx-1 
protein’  
6/2002 – 12/2006 University of Basel: PhD student in immunology 
Supervisor: Prof. Dr. Antonius G. Rolink 
Thesis title: ‘Regulation of murine B cell development and 
function’ 
14.01.2010 University of Basel: PhD exam 
  
Working experience  
since January 2007 Scientist, Head of Bioinformatics, 4-Antibody AG, Basel 
  
Additional working experience  
1988 - 1992 Administrator, Office for Radiation Safety, 
Ciba-Geigy AG, Basel 
1992-1996 IT support, software development and documentation, 
Roche AG, Basel 
1999 - 2000 Research assistant at the Institute for Medical Virology, 
University of Zurich 
2000 - 2002 Web application developer, CIN Technologies, Zurich 
Spring – Fall 2001 Assistant, UBS Private Banking, Zurich 
CURRICULUM VITAE 
   
 
 
150 
  
Further training  
3/2003 Introductory course in laboratory animal science, 
Institute for Laboratory Animal Science, University of Zurich 
12/2007 Education for persons responsible for directing animal 
experiments, 
Institute for Laboratory Animal Science, University of Zurich 
  
Publications  
Chappaz, S., Flueck, L., Farr, A. G., Rolink, A. G. and Finke, D. (2007) Increased TSLP 
availability restores T- and B-cell compartments in adult IL-7 deficient mice. Blood 110 (12), 
3862-70 
Rauch, M., Flueck, L. and Rolink, A. G. (2009) Differential BAFF-R expression enables the 
discrimination between receptor editing and non-receptor editing immature bone marrow B cells. 
In prepraration. 
 
Lectures 
I have attended lectures of the following professors during the time of my PhD studies: 
• Prof. Antonius G. Rolink 
• Prof. Fritz Melchers 
• Prof. Jan Andersson 
• Prof. Daniela Finke 
• Prof. Ed Palmer 
• Prof. Gennaro De Libero 
• Prof. Jean Pieters 
 
 
  ACKNOWLEDGEMENTS 
   
 
  151 
Acknowledgements 
First of all, I would like to thank my doctoral adviser, Prof. Antonius (Ton) G. Rolink, for 
accepting and supporting me as PhD student. He gave me the chance to gain a much deeper insight 
into immunology during every day lab work and through his talks and seminars. It was an awesome 
opportunity to learn from a researcher having such a deep knowledge and being so passionate about 
immunology and research in general. It was a great pleasure to be part of Ton’s research group. 
Many thanks also to Prof. Jan Andersson for the proofreading of my thesis and for always 
supporting me. 
I also like to thank Prof. Ed Palmer for being my co-referent. 
A special thanks goes to Stephan Chappaz and Prof. Daniela Finke for let me take part in the 
collaboration of the TSLP project. 
Furthermore many thanks to all the lab members, especially to Angèle, Corinne, Daniel, Evita, 
Gina, Giuseppina, Kim, Melanie, Nabil, Roxane, Rod and Steffen for all their support and the great 
time we spent together. Many thanks also to Ernst Wagner for taking care of the mice and to 
Hannie Rolink for doing histological work. A special thanks goes also to Melanie Schmid for all 
here administrative support and always being a helping hand. 
I also want to thank Ulf, Sijmen, Jürgen and Marc of 4-Antibody AG in supporting me during my 
thesis writing, while already working for 4-Antibody AG. 
Finally, I want to thank my wife, Charlotte, and my family for their continuous support. 
 
